Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
I. INTRODUCTION

Mucosal surfaces are the interface between the host’s internal milieu and the external environment, and they have dual functions, serving as physical barriers to foreign bodies and pathogenic microbes and providing the foundation for crucial survival functions such as uptake of air and nutrients, reproduction, and perception of signals. The protection of mucosal surfaces is ensured by the specialized mucosal-associated lymphoid tissues (MALTs). Mucosal vaccines, in contrast to parenteral vaccines, generally induce more efficacious protective immune reactions by inducing secretory IgA responses and cell-mediated immunity in mucosal tissues and portals of entries of mucosal pathogens. For food components and inert materials in breathing air, the MALT should remain tolerant so as not to cause unnecessary inflammatory responses. Despite the many advantages of mucosal vaccines, there are only limited numbers of licensed mucosal vaccines. Almost all licensed mucosal vaccines are composed of whole components of pathogens, either live or dead. There is no successful subunit mucosal vaccine so far. Live attenuated or whole cell (WC) killed vaccines are not formulated with any specific adjuvant or delivery system. In those vaccines, pathogen-associated molecular patterns (PAMPs) play the role of built-in adjuvants, and cell corpuscles serve as delivery systems for protective antigens. There could be many reasons for the sluggish progress of development of mucosal vaccines. Concerns about safety are the most prominent reason. Mucosal surfaces are continuously exposed to environmental and food antigens and allergens, and inflammatory immune responses against mucosal vaccine antigens would result in sustained pathologic inflammation. In the case of nasal vaccination, the nasal cavity is separated from the central nervous system by a thin partition, and olfactory nerves are directly projected from the brain to cavity. The scarcity of optimal delivery systems is another reason for the slow progress. In the mucosal environment, there are many physicochemical conditions that...
would interfere with proper stimulation of immune cells by antigens and adjuvants. In the case of oral administration, to be taken up by microfold (M) cells in the distal jejunum and ileum, antigens should be able to accommodate very low pH in the stomach and a sudden alkaline surge in the duodenum, and they should be able to resist proteolytic attacks of digestive enzymes. In contrast to the oral route, antigens delivered intranasally do not experience that dramatic fluctuation in pH, but they should be able to survive profuse mucosal secretions, mucociliary clearance, and the relative inefficiency of antigen uptake by antigen-presenting cells (APCs). For more efficient delivery of mucosal vaccines, many new delivery systems based on nanotechnology and biomaterials have been studied, but very few of them have been approved for clinical use. More vigorous clinically oriented research is needed. 

II. NANO/MICROSCALE CARRIERS AS PROMISING DELIVERY TOOLS FOR VACCINES

In vaccine formulations currently approved or under clinical trials, nanoscale (<1000 nm) carriers are already in use. Current nanotechnology and nanocarriers on the market or in the literature are summarized in Table 19.1 and Fig. 19.1. They include virus-like particles

### TABLE 19.1 Current Nanotechnology and Nanocarriers Used for Vaccine Delivery

| Technology or Nanocarrier | Example (Antigens or Carriers) | Reference |
|---------------------------|--------------------------------|-----------|
| Virus vector              | Adenovirus, vaccinia virus Ankara (MVA), canary pox, yellow fever virus, pox virus, vesicular stomatitis virus, measles virus | Humphreys and Sebastian (2018) |
| Virus-like particles (VLPs) and virosomes | Hepatitis A/B/E virus, human papillomavirus (HPV), influenza, human immunodeficiency virus (HIV), norovirus, respiratory syncytial virus (RSV), SARS-CoV | [3], Fuenmayor, Godia et al. (2017) |
| Emulsions                 | MF59, AS03, AS02, Montanide, GLA-SE | [4], O’Hagan and Fox (2015) |
| Immunostimulating complexes | ISCOM | [5] |
| Monophosphoryl lipid A | AS04, AS02, DETOX, Melacine | [3] |
| Calcium phosphate nanoparticles | CaP, anthrax, hepatitis B virus, influenza | He et al. (2000) |
| Polymeric nanoparticles | PLG, PLA, PLGA, chitosan | Cordeiro et al. (2015) |
| Liposomes                 | Hepatitis virus B/C, RSV, influenza, *Burkholderia, Candida*, malaria, leishmaniasis | De Serrano and Burkhart (2017) |
| Proteosomes               | *Neisseria meningitides*, *Shigella*, *Haemophilus influenzae* type b (Hib), *Streptococcus pneumonia*, influenza | Fries et al. (2001), [3], Burt et al. (2011) |
| Cholesterol-bearing pullulan nanoparticles | Cholesteryl group-bearing pullulan (CHP) nanogel | [6] |
| Self-assembled peptides   | Self-assembled peptide nanostructures with adjuvanticity as well as antigenicity | [7] |
(VLPs), emulsions, liposomes, immunostimulating complexes (ISCOMs), polymeric and nondegradable nanoparticles (NPs), and nanogels [8]. Some of the NPs are able to enter APCs by diverse pathways, thereby differentially modulating downstream immune responses. Moreover, the nano-based delivery systems are also able to carry antigens and specific adjuvants such as TLR ligands simultaneously in the same carriers; carriers by themselves sometimes exert adjuvant activities. The nanoscale vaccine carrier systems generally constitute three key components: an antigen, against which adaptive immune responses are induced; an adjuvant, to potentiate the interaction between innate and adaptive immune systems in reacting to the antigen(s); and a delivery or targeting system to ensure that the antigen(s) and adjuvant(s) are delivered together to the right location at right time [9].

In this context, many effective mucosal delivery systems using the nano/microscale carriers have been very actively researched up to clinical trial levels in recent years.

Viral-vectored vaccines and live or killed virus vaccines by themselves are already nanocarriers with built-in PAMP adjuvants. VLPs and virosomes behave similarly to viruses in stimulating immune responses and carrying antigens in nanoscales. Some adjuvant formulations are already composed of nanoscale structures. Formulation of adjuvants with vaccine antigens became inevitable in modern vaccine development to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities. While early adjuvants (e.g., aluminum, oil-in-water emulsions) were used empirically, rapidly increasing knowledge of how the immune system interacts with pathogens allowed better understanding

**FIGURE 19.1** Different micro/nanocarriers that could be applied to the development of mucosal vaccine delivery systems.
of the role of adjuvants and how the formulation of modern vaccines can be better tailored for the desired clinical benefit [4]. Of interest, currently licensed oil-in-water emulsion adjuvants such as MF59, AS02, and AS03 comprise nanoscale structures in the formulation. Squalene is popularly incorporated in oil-in-water emulsions because of its physical and immunostimulatory properties [10]. MF59 (Novartis Vaccines & Diagnostics), AS03 (GSK Biologics), and glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE) (infectious disease research institute (IDRI)) have a squalene content of around 2%–4% (w/w) with additional emulsifying agents [11]. MF59 was the first oil-in-water emulsion on the market produced by microfluidization and contains sorbitan trioleate and polysorbate-80 (PS80) as surfactants. MF59 has a particle size of around 160 nm [12]. AS03 contains α-tocopherol and PS80 as a surfactant. AS03 has a particle size of about 150 nm [13]. GLA-SE (IDRI) consists of a squalene emulsion in combination with GLA, which is a synthetic form of monophosphoryl lipid A (MPLA) and a potent immunopotentiator. GLA-SE has a particle size of about 100 nm [14]. It has been suggested that emulsions with particle sizes ranging from 100 to 200 nm are efficiently taken up by dendritic cells (DCs) and hence effectively stimulate immune responses against coadministered vaccine antigens [15]. TLR ligands and immunostimulatory agents such as QS21 are formulated into oil-water emulsion or liposomes to make adjuvants for vaccines against diverse infectious agents and tumor immunotherapy. ISCOMs are approximately 40-nm cage-like particles produced by combining protein antigens, cholesterol, phospholipid, and the saponin adjuvant Quil A [5]. ISCOM is composed of matrix serving traps for protein antigens. Typically, membrane antigens containing hydrophobic domains are well trapped in ISCOM through apolar interactions [16].

Liposomes are spherical carriers composed of one or more phospholipid membranes with aqueous core. Thanks to the structure, liposomes provide a wide range of options for vaccine formulation design. Proteins, peptides, DNA, RNA, and adjuvant components can be readily encapsulated inside the aqueous core, embedded within the lipid layer, or attached to the surface by adsorption, hydrophobic anchor insertion, or covalent fusion. Liposomes by themselves are considered to be nontoxic and biodegradable when mainly phospholipids are used, since they are normal components of mammalian cell membranes and lipids are relatively nonimmunogenic. Liposomes could be designed and manufactured to have the desired physicochemical characteristics optimal for inducing desired immune responses against vaccine antigens: vesicle size, lamellarity (number of lipid layers), surface charge, bilayer fluidity, and incorporation of immunostimulatory components [16a].

Polymeric NPs are have also been robustly studied to deliver vaccine antigens and adjuvants. Polymeric NPs are submicron-sized colloidal systems of natural or synthetic polymers used as delivery carriers of chemical drugs, proteins, peptides, and nucleic acids, owing to their high bioavailability, controlled release, biodegradable and biocompatible properties, and low toxic profiles [17]. Compared with liposomes, polymeric NPs can more easily incorporate both hydrophilic and hydrophobic biomolecules and have better storage stability. The most commonly studied polymers are poly(D,L-lactide-co-glycolide) (PLG), polylactide (PLA), and poly(D,L-lactide-co-glycolide) (PLGA) [18,19]. These biodegradable, biocompatible polymers are well characterized and have been approved by the U.S. Food and Drug Administration (FDA) for use in humans because of their excellent safety profiles. They have been extensively studied for the formulation of vaccine antigens (proteins, peptides, DNA, etc.) [20]. In these formulations, antigens can be either entrapped or adsorbed to the surface of the particles and are protected

IV. CURRENT AND NEW APPROACHES FOR MUCOSAL VACCINE DELIVERY
from proteolytic degradation conferring longer half-lives in vivo. By not-so-difficult additional engineering, these particles can be regulated to degrade or to release cargos (adjuvant and/or antigens) over a wide range of rates. Additionally, polymeric particles more easily pass M cells and reach to APCs in the MALT after surviving harsh physicochemical conditions in many mucosal compartments [3,18].

PLG polymers have been evaluated for drug delivery since the early 1980s and have been used widely for pharmaceutical and medical device applications with excellent safety profiles in humans [21]. Generally, PLG forms microparticles rather than NPs. PLG microparticles received attention for vaccine delivery by the World Health Organization (WHO) Special Program for Vaccine Development from the late 1980s [22]. Triggered by this program, many antigens, such as tetanus toxoid, hepatitis B antigen, and diphtheria toxoid, were formulated with PLG microparticles and evaluated in comparison with aluminum salt adjuvants [21]. Although some promising results with PLG-based vaccines in small animal models were reported, challenges concerning antigen stability and insufficient immune responses compared with alum-adjuvanted vaccines prevented the use of PLG microparticles in commercial vaccines [23]. One more disadvantage of PLG polymer-based vaccines is their inefficiency in translocating to lymph nodes where APCs present antigens to T lymphocytes. The particle size can influence transport to specific location and cell types in the draining lymph nodes [24,25]. NPs (20–200 nm) drained to the lymph nodes and localized in the lymph-node-resident DCs and macrophages, whereas larger particles (500–2000 nm) were mostly associated with DCs at the injection site. PLG particles would be inefficient in presenting antigens to DCs in draining lymph nodes. In this regard, PLG microparticles have handicaps to being more widely applied to the development of vaccine delivery systems.

PLA is a linear aliphatic polyester composed of lactic acid building blocks that are naturally occurring organic acids derived from sugarcane and cornstarch [9]. PLA’s physical properties can be tuned through combining racemic mixtures of these enantiomers: poly-L-lactide and poly-DL-lactide semicrystalline and amorphous polymers, respectively [26]. Thanks to their good safety profiles, PLA-based products have been approved by the FDA and the European Medicines Agency (EMA) for multiple biomedical applications. This polymer can be easily chemically modified with different ligands to improve their specificity to targeted cells [27]. In vivo, PLA is hydrolyzed into α-hydroxy acid, which is easily metabolized in the body via the Krebs cycle [28]. PLA polymers can be fabricated into both microparticles and NPs [27]. Despite its physicochemical and pharmaceutical advantages, PLA has been less intensively applied than other polymers, such as its copolymer PLGA, in clinical stage vaccine developments. Although a considerable number of reports have shown the usefulness of PLA polymer NPs as versatile vaccine carriers, the scaling-up of these laboratory methods to industrial production has faced hurdles, which are mostly related to particle size and size distribution. For further development of PLA polymers as clinical-grade vaccine delivery systems, these practical problems need to be solved in advance.

Biodegradable nano/microparticles of PLGA and PLGA-based polymers are more widely explored as carriers for controlled delivery of macromolecular therapeutics such as proteins, peptides, vaccines, genes, antigens, and growth factors. PLGA is one of the most successfully developed biodegradable polymers. Among the different polymers developed to formulate polymeric NPs, PLGA has won strong attention, owing to its attractive properties: biodegradability and biocompatibility, FDA and EMA approval in drug delivery systems for parenteral administration, well-described
formulations and methods of production adapted to various types of drugs such as hydrophilic or hydrophobic small molecules or macromolecules, protection of the drug from degradation, the possibility of sustained release, the possibility of modifying surface properties to provide stealthiness and/or better interaction with biological materials, and the possibility of targeting NPs to specific organs or cells [29]. The PLGA-based carriers’ cargo release characteristics could be relatively well controlled by modulating encapsulation, particle size, formulation additives, molecular mass, ratio of lactide to glycolide moieties in PLGA, and surface morphology [30]. The most widely used PLGA, with a monomer composition of 50:50, has the fastest biodegradation rate; it completely occurs in approximately 50–60 days. The polyglycolide acid is more hydrophilic than polylactide, owing to the absence of a methyl side group [31]. A higher glycolic acid percentage causes more water uptake and consequently faster degradation of PLGA polymers. PLGA is hydrolyzed into the original monomers lactic acid and glycolic acid, which are by-products of various metabolic pathways and are not associated with any significant toxicity except lowered pH. Next to release characteristics, various other physical traits of PLGA particles can be manipulated, including particle size, size distribution, zeta potential, polydispersity index, encapsulation efficiency, and cargo loading [32]. Among a myriad of choices in nano/microcarrier polymers, PLGA has more advantages other than those listed above: PLGA particles can be administered via diverse routes; PLGA particle formulation may dampen toxicities of vaccine components; PLGA particles could protect the antigen from degradation and allow controlled release; PLGA particles could be made to target APCs and increase cross-presentation of the antigen; and PLGA particles allow concomitant delivery of multiple vaccine components with dose sparing. While many properties of PLGA polymers are favorable and controllable as vaccine delivery tools, there are drawbacks as well. PLGA has a negative effect on the stability of encapsulated protein antigens during preparation and storage, primarily owing to the acid-catalyzed nature of its degradation. Its hydrolysis leads to the accumulation of lactic and glycolic acids in the microenvironment, which will denature encapsulated protein antigens and consequently compromise immunogenicity [30]. In addition, processing conditions used in manufacturing PLGA carriers have negative effects on protein secondary structures [33]. To overcome problems associated with protein degradation, many efforts have been made to optimize the manufacturing process and to add excipients that would protect the protein antigens being encapsulated. Protein antigens adsorbed to PLGA particles are relatively more protected from those physicochemical insults. Adsorbed antigen would offer improved stability and activity over encapsulated antigen by avoiding exposure to organic solvents used during formulation and acidic pH conditions caused by degradation of the polymer. But this may result in premature high burst release of the antigen before uptake by APCs, which can lead to deficient immune responses [34].

Natural polymers are attractive vaccine delivery vehicles, owing to their low toxicity and biocompatibility. Synthetic polymers such as PLGA or PLA are also reported to be safe and biocompatible. Their degradation products affect the microenvironment by lowering pH which may be detrimental to functions of APCs and compromise immunogenicity of vaccine antigens. On the other hand, natural polymers are generally composed of biological components, making them physiologically resorbable with few to no adverse effects [35]. The major drawback of natural polymers as vaccine delivery systems is reproducibility, which should be overcome by further technological researches. There are two major groups of
natural polymers that are used to manufacture particulate carriers: peptide/proteins and polyelectrolytes including alginate, chitosan, and dextran [36]. Chitosan and chitosan derivatives are cationic polymers, which, owing to their structure, have excellent mucoadhesive and absorption-promoting properties. Chitosan is manufactured by alkaline deacetylation of chitin (e.g., derived commercially from exoskeletons of crustaceans or fungi) and is a linear copolymer of $\beta$-1-4 linked monomers of D-glucosamine and N-acetyl-D-glucosamine [36]. It is biodegradable and biocompatible. The pKa of the primary amine group of chitosan is approximately 6.5, and the nascent polymer at neutral pH carries no charge; hence chitosan is insoluble in water. This solubility characteristic should prevent nascent chitosan from being able to deliver antigens that are soluble and stable at neutral pH. Structural modifications have been made to chitosan to produce derivatives that are soluble at neutral pH yet retain the positive charge and unique properties of nascent chitosan. Because chemical modifications make it possible to substitute both amine and hydroxyl functional groups of chitosan, various chitosan derivatives have been produced by introducing hydrophilic groups such as hydroxyalkyl, carboxyalkyl, succinyl, thiol, and sulfate or by grafting solubility enhancer polymers such as polyethylene glycol and poloxamer [37]. Of all the water-soluble derivatives, N-trimethyl and carboxymethyl derivatives of chitosan have been studied most extensively, owing to their relative ease of synthesis, ampholytic character, and ample application possibilities. Soluble N-trimethyl chitosan has both mucoadhesive properties and excellent absorption-enhancing effects even at neutral pH because of its cationic charge at neutral pH [38]. N-trimethyl chitosan is rather widely applied to the development of mucosal vaccine delivery systems, since it is mucoadhesive and has penetration-enhancing ability through the paracellular route even at neutral pH. Chitosan particles can be fabricated to successfully deliver both adjuvant and antigen to DCs in the tissue or draining lymph nodes [39]. Adjuvants and antigens could be either incorporated inside or adsorbed on the surface of chitosan microparticles or NPs on purpose. In addition to being a carrier, chitosan can be used to coat other polymer particles to enhance their immunogenicity, bioadhesiveness, and surface adsorption potential [36]. N-trimethyl chitosan is freely soluble over a wide pH range as compared to other chitosan derivatives and bears positive charges, independently of the environmental pH. Methylcarboxy chitosan is a polyampholytic polymer that is able to form viscoelastic gels in aqueous environments or with anionic macromolecules at neutral pH values. On the basis of these characteristics, the complexation of two chitosan derivatives without using any cross-linker could generate a vaccine delivery carrier that has high loading efficiency and can maintain integrity of a protein antigen [40]. Alginate is a linear, anionic polysaccharide found in the cell walls of brown algae. It has a high affinity for water and forms an inert and highly aqueous environment within the particle, which limits its ability to carry hydrophobic vaccine antigens and adjuvants. It is also biocompatible, biodegradable, and easily eliminated from the body [36,41]. As with chitosan particles, adsorption of adjuvant onto the surface of microspheres allows differential release of the antigen and adjuvant for temporally controlled stimulation of immune cells [42]. Alginate itself, besides its role as a vaccine carrier, has immune-stimulatory activities though stimulating NF-$\kappa$B signaling pathway [43]. Dextran is a polysaccharide composed of repeating branched glucose molecules. Its most commonly used form is dextran sulfate [44], which is biocompatible and hydrophilic and decomposes into natural by-products. Anionic dextran sulfate is often fabricated with cationic poly-L-arginine to make layer-by-layer antigen-adjuvant carriers
Because this type of particle is assembled layer by layer, multiple antigens and adjuvants can be incorporated in multiple layers to maximize targeting and activation of immune cells.

Self-assembled peptides have been reported to be useful candidates for future vaccine delivery systems [7]. Peptide molecules can be rationally designed to self-assemble into specific nanoarchitectures in response to changes in their assembly environment, including pH, temperature, ionic strength, and interactions between host and guest molecules. They could be manufactured in the forms of nanomicelles, nanovesicles, nanofibers, nanotubes, nanoribbons, and hydrogels and would have a diverse range of mechanical and physicochemical properties [46]. Peptide delivery systems may have potential advantages over liposome or NPs, since they can be composed of amphiphilic molecules with high loading efficiency, low antigen leakage, biodegradability, and high permeability to biomembranes of target cells. These molecules can be designed for cell-specific targeting by including adhesion ligands, receptor recognition ligands, or peptide-based antigens in their design, often in a multivalent display [7]. These molecules can also act as intracellular transporters and respond to changes in the physiological environment. Generally, self-assembling peptides are nonimmunogenic, serving as built-in adjuvants for fused antigenic peptides [47]. The adjuvant activity is closely related to nanostructures, since the mutation of key amino acid residues in the self-assembling domain demolishes the immunogenicity of the self-assembled peptide vaccines [48]. The adjuvanticity in a nanofiber self-assembled peptide vaccine was reported to be T-cell- and MyD88-dependent, but specific interactions with TLR2 and TLR5 as well as NALP3 were not noted, suggesting a novel immunomodulating mechanism. Although peptide nanofiber vaccines are more efficiently taken up by DCs and subsequently activate them, these vaccines do not cause reactogenicity and nonspecific inflammatory reactions at the administration site [49].

Nanogels became more prominent recently as a vaccine delivery system. The term “nanogel” defines refers to nanoscale particles (<100 nm in diameter) composed of physically or chemically cross-linked bifunctional networks having good swelling capacity in aqueous environments [50]. Nanogels have a high cargo loading capacity, biocompatibility, and biodegradability. Cationic nanogels are adhesive to epithelial cell surface and serve as artificial chaperones protecting antigens from aggregation and denaturation. Loaded antigens are subsequently released in native forms and captured by appropriate APCs nearby [51]. The surfaces of nanogels are relatively easy to modify by specific ligands, enabling targeted delivery to specific cells or tissues. Nanogel vaccine formulations can be delivered via a wide range of routes, such as parenteral, oral, nasal, pulmonary, or ocular administration [52]. Nanogels can be formulated by various polysaccharides such as chitosan, mannan, hyaluronic acid, dextrin, cycloamylose, pullulan, and enzymatically synthesized glucogen [53]. In recent years, pullulan has played a critical role in the development of nanogel systems for vaccine and drug delivery [54]. Pullulan is an aqueous polysaccharide synthesized by the yeast-like fungus Aureobasidium pullulans. It consists of hundreds of repeated units of a maltotriose trimer. Pullulan is widely used in diverse biomedical industries because it is easily modified by rather simple chemical reactions that are nontoxic, nonmutagenic, noncarcinogenic, and, most important, nonimmunogenic [55,56]. Pullulan hydrophobized by cholesterol becomes amphiphilic and forms self-aggregates [57]. The cholesterol-bearing pullulan (CHP) can form complex NPs with various protein antigens. CHP can self-assemble in water into the NPs and encapsulate protein antigens in the internal space through hydrophobic interactions. The complex NP protects internal protein
antigens against physicochemical or enzymatic degradation, serves as an ideal delivery vehicle, and releases payloads in a controlled fashion [58]. The most valuable characteristic of CHP nanogels is its artificial molecular chaperon activity [59]. Protein antigens are captured in denatured form in the CHP nanogel under reversible denaturation temperature or in the presence of reversible denaturation reagents [60]. In the nanomatrix, the nanogel protects denatured protein antigen as an artificial molecular chaperone and helps in proper refolding after release [61]. Another advantage of CHP is its targeting ability to APCs. The CHP nanogels and protein antigens could form colloidally stable NPs 50 nm in diameter, which is a relevant size allowing effective uptake by epithelial cells and APCs [59]. Moreover, CHP nanogels can be modified to have cationic charge (cCHP) by adding amine groups to the CHP nanogels [62]. The cCHP nanogels could be well formulated with protein antigens and effectively carry vaccine antigen to the negatively charged nasal epithelium after intranasal administration [51]. The positive charge of cCHP nanogel provides more efficient adhesion to negatively charged nasal mucus and epithelia, leading to higher level and more sustained delivery of antigens to DCs inhabiting underneath mucosa. More important, the cCHP vaccine formulation could induce significantly higher immune responses without adjuvant addition, while the cCHP nanogel itself could not activate immature DCs, suggesting no biologically active adjuvant-like activity [51,63]. The reason why cCHP, having no direct stimulatory effect on innate immune cells, could significantly enhance the immunogenicity of cargo antigens was thought to be the improved antigen residence time in the nasal cavity, which leads to better antigen transport to the nasal DCs. The 40-nm cCHP nanogels carrying Clostridium botulinum type A neurotoxin heavy-chain C-terminus (BoHc/A) were bound by nasal epithelial cells and subsequently endocytosed. The BoHc/A antigen was separated from the nanogel by protein exchange and sustainably released by exocytosis, which was subsequently taken up by CD11c+ DCs in the mucosa [51]. Epithelial cells served as a reservoir for the cargo antigen, while no overt cytotoxicity was observed. Neither the cCHP nanogel nor cargo BoHc/A antigen was taken up by the olfactory bulb or brain tissue, suggesting that the cCHP nanogel system is safe for nasal administration (Chapter 26: Nanodelivery for Mucosal Vaccines).

### III. MUCOSAL VACCINE DELIVERY: PAST, PRESENT AND FUTURE

#### A. Oral Vaccine Delivery

Gastrointestinal (GI) infection is a significant global health challenge, especially in developing countries. Most GI infections are spread via the fecal–oral route, primarily through contaminated water and food due to poor sanitation and social infrastructure. An efficacious vaccination policy is the most economical way of solving GI infection problems from a public health perspective. The oral vaccination is generally the best way to induce secretory immunoglobulin A (SIgA) in the GI tract and IgG antibody responses in the systemic compartment. In fact, the only oral vaccine that has been widely used globally in infants and children in a national immunization program is the oral polio vaccine (OPV) developed by Albert Sabin in the 1950s. Since Sabin’s OPV vaccination, several oral vaccines against rotavirus, Salmonella Typhi, and Vibrio cholerae have been licensed and marketed [64]. Those vaccines are made of live attenuated organism or killed microbial cells. There is as yet no licensed subunit oral vaccine on the market. There have been continuous efforts to develop oral vaccines because of the advantages of oral vaccination. As was noted during the 2010 Haitian
cholera epidemic, oral vaccination is a faster way of containing circulating infections and prevention of further outbreaks [65]. After the September 11, 2001, terrorist attacks, the threat of biological warfare became highlighted worldwide. The potential bioterrorism agents are likely to be disseminated by either aerosol or in food or water supplies targeting the wide mucosal surfaces in the respiratory or GI tracts, respectively. Considering that the bioterrorism agents invade from the GI mucosa, oral vaccines, inducing protective immune responses at the route of entry, have generated the most interest as a frontline tool in biodefense [66].

1. Advantages and Limitations of Oral Vaccines

Oral vaccination has several advantages, such as better patient compliance, mass immunization capability, easy administration or self-delivery, simplified production and storage, lower production cost, and no needle-associated risks such as injuries and carryover infections (Table 19.2) [67]. The most important virtues of oral vaccination are its needle-free painless administration and that there is no need for trained personnel for administration. Two major mucosal vaccination routes, oral and intranasal, are compared in Table 19.3. The most widely used oral vaccine is Sabin’s OPV, which contributed enormously to the eradication of poliomyelitis worldwide. But recently, despite its efficacy, OPV has been replaced by injectable poliovirus vaccine (IPV) in developed countries. OPV is likely to be replaced by IPV globally over several coming years. Live poliovirus was discovered in the stool of OPV vaccines, possibly spreading infectious material in the environment [68]. Another serious concern about OPV is the rare event of reversion to virulent strains in vivo, which could cause a serious iatrogenic vaccine-associated paralytic poliomyelitis [69]. The same concerns apply to other mucosal vaccines using live attenuated organisms. But generally, oral vaccines are regarded as a better choice than injectable parenteral vaccines from production, economic, and regulatory perspectives [70]. Oral vaccines have better compliance and fewer adverse reactions. Oral vaccines are better for large-scale production and mass vaccination campaigns in developing countries, since no needles are required and self-administration is possible. Thermostabilization technologies would enable successful cold-chain-free vaccination of killed as well as live attenuated formulations in resource-poor settings such as developing countries [71].

Thanks to the many virtues of oral vaccines and the success of OPV, research into oral vaccines has rather a long history, but only a very limited number of oral vaccine products have become available. Many oral vaccines that proved to be efficacious in preclinical studies have failed in clinical trials. Live-attenuated vaccines against rotavirus and S. Typhi have been successfully introduced into the market. In the case of cholera, two types of oral cholera vaccines (OCVs) are currently available: WC-rBS, which are killed WC monovalent (O1) vaccines with a recombinant B subunit (rBS) of cholera toxin (CT) (Dukoral), and killed modified WC bivalent (O1 and O139) vaccines without the B subunit (Shanchol, Euvichol, and mORCVAX) (WHO cholera vaccine position paper—August 2017 at www.who.int) (Chapter 31: Cholera Immunity and Development and Use of Oral Cholera Vaccines for Disease Control). The three WC vaccines are based on the same cholera strains and dosage. Although the WC killed cholera vaccines listed proved to be efficacious in multiple clinical trials, many other prototype killed and subunit vaccines could not be put on the market because of suboptimal immunogenicity. Oral vaccines should have strong immune-stimulatory adjuvants and optimal delivery strategies to drive effective innate and adaptive immune responses against vaccine antigens [64]. To achieve optimal immunogenicity, Dukoral has a huge number of killed V. cholerae cells (1.25 × 10^{11} CFU) and 1 mg of rBS. The three bivalent WC vaccines contain 2100 LPS ELISA unit of killed cells. Vaxchora,
TABLE 19.2 Common Oral Delivery Systems and Their Advantages and Disadvantages

| Delivery System | Application | Advantages | Disadvantages |
|-----------------|-------------|------------|---------------|
| Solution        | Live attenuated, whole cell killed, proteins, peptides, conjugates | Inexpensive buffer, flexible, easy administration | Often requires the use of bicarbonate salts to neutralize gastric acid, dilution of formulation, lack of clean water in poor regions |
| Emulsions       | Whole cell killed, proteins, peptides, conjugates | Potential for different formulations to facilitate specific immunomodulation, for example, Th1 (water-in-oil) and Th2 (oil-in-water) | Does not protect vaccine from GI tract harsh environment, efficacy by the oral route uncertain, no licensed oral vaccine yet |
| Virus-like particles | Plasmid DNA, proteins, peptides, conjugates | Nonreplicating, high uptake, self-assembling, can conjugate additional molecules for targeted tissue/cell specificity and immune modulation (adjuvant) | Expensive and difficult to scale up, requires purification and often formulation with additional adjuvants, no licensed oral vaccine yet |
| Liposomes       | Proteins, DNA, peptides | Ease of surface modification, can accommodate a wide variety of antigen types, controlled release | Poor antigen loading efficiency, low stability, nonspecific interactions, toxicity of cationic liposomes, degradation by bile salts and lipases in the small intestine |
| ISCOMs          | Proteins, peptides | Intrinsic adjuvant capabilities, ease of antigen loading and surface modification, efficient induction of CTLs | Difficulty of loading hydrophobic antigens |
| Synthetic and natural particles | Proteins, peptides, conjugates | Highly adaptable, can protect contents from both environmental and physiological effects, controlled release, modifiable surface chemistry, carrier size can be engineered | Low loading efficiency, manufacturing process may degrade antigens, surface antigen exposed to proteolysis, can become trapped in mucus, difficulty to scale up |
| Pills and capsules | Live attenuated, whole cell killed, proteins, peptides, conjugates other delivery systems | Highly adaptable, can protect contents from both environmental and physiological challenges, controlled release, two or more carriers could be coformulated, easy administration | Formulation process may damage components, loading complications |

a newly licensed single-dose OCV, contains $2.0 \times 10^8$ to approximately $2.0 \times 10^9$ CFU of live attenuated CVD 103-HgR cells [72–74]. The reason why oral vaccines manufactured with live attenuated organisms or high-dose WC killed bacteria are on the market reflects the poor delivery efficiency and the consequent higher requirement of built-in adjuvants (PAMPs).

2. Oral Vaccine Delivery Systems

A. EMULSIONS AND MICELLES

Emulsions such as MF59 and AS03 are extensively tested for many vaccines and immunization routes. However, in the literature, it is rather rare to find successful test results for oral vaccines against infectious diseases employing...
TABLE 19.3 Comparison of the Intranasal Vaccination Route With the Oral and Parenteral Routes

| Vaccine Route | Advantages | Disadvantages |
|---------------|------------|---------------|
| Intranasal    | Needle free, noninvasive | Short nasal residence time |
|               | No cross-contamination | Quick clearance by mucociliary action |
|               | Amenable for mass vaccination | Need for adjuvants/delivery systems for subunit vaccines |
|               | Self-administration possible | Requires higher antigen dosage than parenteral vaccination |
|               | Increased compliance of vaccines | Limitations for live vaccines (e.g., certain age and risk groups) |
|               | Cost-efficient logistics | Shedding of live vaccine organisms |
|               | Large absorption surface area | Administration problems in vaccines with nasal obstruction |
|               | Reduced risk of anaphylactic shock due to slow absorption | |
|               | Stimulates both mucosal and systemic responses | |
|               | Responses at distant mucosal sites through common mucosal system activation | |
|               | Avoidance of first-pass metabolism | |
|               | No antigen degradation in the stomach | |
| Oral          | Needle free, noninvasive | Inaccurate dosage/low bioavailability |
|               | No cross-contamination | Need for adjuvants/delivery systems for subunit vaccines |
|               | Amenable for mass vaccination | Requires higher antigen dosage than parenteral vaccines |
|               | Self-administration | Site-restricted mucosal responses |
|               | Increased compliance of vaccines | Gastric degradation |
|               | Cost-efficient logistics | First-pass metabolism of antigens |
|               | Stimulates both mucosal and systemic responses | Shedding of live vaccine organisms |
|               | Permissive to low antigen purity | Administration problem in vaccines with accelerated enteric transit (e.g., diarrhea) or small children |
| Parenteral    | Accurate dosage | Invasive |
|               | Fast absorption rate | Poor acceptance by vaccines |
|               | No shedding | Medical trained personnel required |
|               | Strong systemic immune responses | Reduced patient’s compliance |
|               | No gastric degradation | Expensive logistics |
|               | | No stimulation of mucosal responses |
|               | | Poor protection against mucosal infection/colonization |

an oil-in-water or water-in-oil emulsion formulation or adjuvant system. A successful oral tumor vaccine study showed that an antigen complex (melanoma antigen MAGE1, heat shock protein 70, and staphylococcal entero-toxin A) incorporated in a nanoemulsion with a small size of 15–25 nm induced efficacious protective immune responses comparable to those of subcutaneous administration [75,76]. Vaccine antigen can be delivered inside the core or attached on the outside to the shell of micelles, depending on the electrochemical properties of the vaccine formulation [77]. Oral immunization of PLA-PEG-PLA and PLGA-PEG-PLGA copolymer micelles loaded with DNA encoding HCV multiple epitope antigen could induce satisfactory immune responses [78]. The copolymers showed an innate adjuvant activity and caused no significant adverse reactions [78]. Micelles can be synthesized as nanocarriers and engineered to penetrate mucus and be taken up by mucosal APCs [79]. However, micelles may have a propensity to dissociate when diluted, leading to a loss of loaded antigen.
IV. LIPOSOMES

While most clinical trials and delivery system developments employing liposomes have focused on the parenteral routes, there are still continued efforts to develop liposome-based oral delivery tools [80]. Conventional liposomes are vulnerable to acidic gastric juice and are easily digested by pancreatic lipase [81]. Also, intestinal bile salts can destroy the phospholipid membrane integrity and lyse the liposomes, resulting in the premature release of vaccine antigens [82]. To tackle these problems, researchers have investigated different lipid moieties such as archaeal lipids or bile salts in the liposomal membrane [83,84]. An important determinant of the adjuvanticity of liposomes is the surface charge. Positively charged (cationic) liposomes have been demonstrated to possess the strongest adjuvanticity compared to neutral and negatively charged liposomes [85]. Mucoadhesion is promoted by the cationic surface charge that would have a stronger interaction with negatively charged GI mucus. Cationic liposomes also better adhere to negatively charged membranes of M cells and enterocytes, limiting flushing by peristalsis and providing a better chance to be internalized [86]. However, the greater toxicity of cationic than anionic liposomes is of concern. Recently, a study reported that cationic liposomes induce necrosis to release damage-associated molecular patterns and cause inflammation in vivo [87]. To extend the clinical applications of liposomes as carriers of oral vaccines by improving stability and sustainability in GI tract mucosa, the surface modification of liposomes has been rigorously investigated [88–90].

V. IMMUNOSTIMULATING COMPLEXES

The addition of cholesterol and Quil A saponin to liposomes results in the generation of self-assembling pentagonal dodecahedrons that have intrinsic adjuvant properties and thus earned the name ISCOMs. Two types of ISCOMs exist. The first, “classical” type was manufactured to entrap protein antigens, making them act as both a vaccine antigen delivery and an adjuvant system. The second type, referred as ISCOM matrices, contains no entrapped antigen and serves as a codelivered adjuvant, which is later formulated with vaccine antigens. Early ISCOM formulations could not be evaluated in humans and were limited to veterinary use, owing to the reactogenicity of Quil A. Quil A was later replaced with QS21, and ISCOMs could be then given clinical trials. QS21 is more purified in nature and shows an improved safety profile while remaining active as an adjuvant [16]. While ISCOMs were widely tried with very diverse antigens for parenteral and intranasal vaccination studies, trials with oral vaccines have been relatively scarce [91,92]. One major challenge in working with ISCOMs is the difficulty associated with antigen incorporation. In this context, many trials used ISCOM matrices purely as adjuvants and formulated with vaccine antigens rather than incorporating them, which elicited immune responses as beneficial as those elicited by classical ISCOMs [93]. The use of unmodified ISCOMs as adjuvants would significantly simplify production; however, the benefit of antigen encapsulation, which is an important key to success for the oral route, might be lost. For this reason, ISCOM matrix adjuvants in combination with enteric vaccine antigens are used for boosting through intranasal or parenteral routes after oral priming with antigens only or antigens with other adjuvants [92,94–96]. To use ISCOMs for the induction of efficacious immune responses in the GI tract, the immunization protocol employing intelligent oral or injectable prime-boost regimens and incorporating additional coatings or adjuvants should be tried.
VI. VIRUS-LIKE PARTICLES

VLPs imitate the three-dimensional conformation of real virus and mimic infection by authentic viruses. Moreover, VLPs can be engineered to express additional antigens and target epitopes in repeated array. VLPs have been studied as oral vaccines against virus or tumor antigens [97–104]. Those VLP oral vaccines induced humoral and cellular immune responses in both systemic and mucosal compartments. Significant antigen-specific SIgA responses were also observed. VLPs could also be expressed in plant tissue successfully [103,105,106] and could be purified from plant tissue at lower cost. On the other hand, rather crude freeze-dried plant tissue containing VLPs could be directly administered orally to induce protective immune responses in animals, which suggests the possible development of human edible vaccines using VLPs expressed in plant tissues such as tomato and potato [103,107–110].

VII. POLYMERIC PARTICLE-BASED ORAL DELIVERY

Synthetic particles can serve as the most versatile oral delivery tools in which vaccine antigens and adjuvant could be loaded by encapsulation, conjugation, or adsorption. With advances in polymer material chemistry and formulation technology, different types of natural and synthetic NPs are being actively tested for possible use for effective oral vaccine delivery. These recent technologies enable overcoming previous barriers in oral vaccination and allow better targeting of antigens and adjuvants to the desired tissue location and cells. Particles can be engineered to release antigens and adjuvants upon degradation, swelling, and diffusion from the polymer, or change in electrostatic interactions. The production of particles in defined sizes, architectures, and chemical properties would enable oral delivery, which is the most difficult vaccination route in terms of targeted delivery, thanks to the major development in nanotechnology and biomaterial science. Depending upon the polymer choices, the delivery systems by themselves provide adjuvant activity along with biocompatibility and biodegradability. The most extensively studied biodegradable polymers for the development of oral vaccine nanocarriers are PLA, PLGA, β-glucans, alginate, and chitosan [8,111].

In the case of oral delivery, the greater surface area of NPs, owing to their small size, would allow increased absorption across the intestinal epithelium, which will furnish reduced dosage and administration volume [67]. Hydrophilic NPs are generally transported through enterocytes, whereas hydrophobic polymeric NPs are better transported through M cells [30,99,112,113]. Orally administered PLA NPs (200–250 nm) reached the Peyer’s patches (PPs) through a three-step process. Most particles are first entrapped in the mucus. Then crossing of the epithelial barrier takes place exclusively through M cells, leading to an accumulation in PPs. Finally, the NPs interact with underlying B cells and DCs in the PP tissue. All three steps can occur within 15 minutes. Furthermore, DCs engulfing NPs were induced of TLR expression [114]. To be licensed and clinically used for mucosal vaccine delivery, nanocarriers should be able to protect the payload from degradation, to penetrate the mucus barriers, and to control the release of both antigens and adjuvants at targeted sites. In principle, these properties could be tuned by altering their particle size, surface chemistry, and three-dimensional architecture [79]. It is widely accepted that particulate antigens are more efficiently trafficked across the mucosa and delivered to mucosal APCs than are soluble antigens [67]. Uptake of particles in the GI tract occurs primarily via M cells. Despite some controversies, particles with a diameter smaller than 1 μm are thought to have a better chance of being taken up by M cells [115].
To meet requisites for delivering diverse vaccine antigens and adjuvants to a specific mucosal target, PLGA surface characteristics have been extensively modified by coating with ionic surfactants or polymers such as polyethylene glycol (PEG), sodium dodecyl sulfate, amino-dextran, chitosan, polyethylene imine, poly-L-lysine, protamine, or cetyltrimethylammonium [30,116–118]. The surface chemistry of PLGA particles can also be altered to increase diffusion through mucus and uptake by M cells through oral delivery [119,120]. Other methods, such as coating antigen/adjuvant-loaded PLGA NPs with methacrylate-based polymer Eudragit FS30D, produced gastric-acid-resistant micro-particles (≥10 μm) that released payloads from the terminal ileum, where the pH level reaches 7.0 or higher [121]. The pH-sensitive polymers derived from methyl methacrylate, methacrylate, methacrylic acid, acrylate, and/or dimethacrylate have been blended with PLGA for the protection of payloads in the NP against enzymatic attacks in the stomach and small intestine [122]. The antigen encapsulated by PLGA NPs sequentially coated with phase-transitional shielding layer, poly[(methyl methacrylate)-co-(methyl acrylate)-co-(methacrylic acid)]−poly(d, L-lactide-co-glycolide) (PMMMA-PLGA), was found to protect antigens in the GI tract and achieve targeted vaccination in the large intestine [123]. Hydroxypropyl methylcellulose phthalate (HPMCP), another enteric coating agent, was shown to make acid-resistant ~200-nm NPs with PLGA carrying Helicobacter pylori antigen effectively induce Th1/Th17 protective immune responses [124].

To induce enhanced protective immune responses against antigens delivered by PLGA carriers, PLGA particles are functionalized by M-cell-targeting ligands in combination with stabilizing agents. Incorporation of M-cell-targeting lectins such as UEA or LTA into PLGA NPs would enhance antigen-specific immune responses [125,126]. Arginine-glycine-aspartate (RGD) ligand binding to β1 integrin can also target M cells. PEGylated PLGA NPs grafted with RGD or RGD peptidomimetic ligand showed significantly increased uptake by M cells and enhanced specific IgG responses [113,127]. Claudin 4, one a member of the integral membrane protein family expressed primarily in tight junctions, also serves as a target for developing M-cell-binding nanocarriers [128]. In one study, an antigen-loaded porous PLGA microparticle was successfully coated with water-soluble chitosan conjugated with an M-cell-targeting peptide (CKS9). The resulting microparticles effectively reached PPs through M cell transcytosis to induce balanced Th1/Th2-protective immune responses [129,130]. The pH-sensitive polymeric delivery systems employing hydroxypropyl methylcellulose phthalate (HPMCP) could be attuned by adding thiol groups to be selectively released under ileal pH condition. By formulating M-cell-homing peptide (CKSTHPLSC) conjugated BmpB antigen with attuned HPMCP, delivery to PPs and subsequent adaptive immune responses could be significantly enhanced [131,132].

Recent research into oral vaccine delivery of NPs has been directed toward the incorporation of mucoadhesive polymers. The mucoadhesive polymers prolong retention time of the particles in the mucus by steric or adhesive interactions. Coating of nonbioadhesive nanoparticles with poly(butadiene-maleic anhydride-co-L-DOPA) increased the particle uptake by 10-fold in the small intestine [133]. Conjugation of immunostimulatory ligands to bioadhesive polymers should induce longer-lasting mucosal and systemic immune responses against entrapped antigens. Bioadhesive poly(anhydride) NPs (300–400 nm) coated with mannose or Salmonella flagellin induced more potent and balanced Th1/Th2 immune responses compared with noncoated particles [134].

Chitosan and its derivatives have been tried for the oral delivery of protein and DNA vaccines [135–139]. The limited solubility of chitosan at alkaline and neutral pH has been
circumvented by fabrication of chitosan by graft copolymerization with acyl, alkyl, monomeric, and polymeric moieties. Modifications through quarterization, thiolation, acylation, and grafting resulted in copolymers with higher mucoadhesion strength, increased hydrophobic interactions (advantageous in hydrophobic antigen entrapment), and increased solubility in alkaline pH, higher solubility, and controlled/extended release profiles, which consequently confer wider application of chitosan derivatives for oral vaccine delivery [140,141]. Chitosan and its derivatives are mucoadhesive and have the ability to stimulate immune cells either by directly interacting with the M cells or by opening the tight junctions between the epithelial cells [142]. Because of the advantages mentioned above, chitosan has been applied to the manufacture of orally deliverable NPs or coating of micro/nanocarriers made of other synthetic or natural biopolymers [143,144]. Alginate has been used to make oral vaccine carriers utilizing its acid resistance and immunostimulatory properties [145]. In order to overcome chitosan’s instability in low-pH environments, cationic chitosan NPs can be coated with acid-resistant alginate to make composite carriers [144,146]. Alginate encapsulation of chitosan NPs entrapping protein antigens was proved to protect payload protein antigens and DNA from acidic attack in the stomach after oral administration. Owing to its acid resistance property, alginate is also used to encapsulate bacterial cells to develop oral vaccines. A single oral dose of alginate-encapsulated BCG elicited effective long-lasting mucosal and systemic immune responses [147]. Cold-chain-free OCV could be developed by encapsulating heat-inactivated bacterial cells with alginate [148]. Oral vaccines against Edwardsiella, Brucella, and Aeromonas infections were also developed by encapsulation with alginate [149–152].

Glucan particles are porous 2- to 4-micron cell wall shells manufactured by treating baker’s yeast (Saccharomyces cerevisiae) with a series of alkaline, acid, and solvent extractions [153]. By in situ layer-by-layer synthesis through electrostatic interactions, DNA could be encapsulated at high density [154]. Protein antigens could be encapsulated in glucan particles through hydration and lyophilization and could induce significant intestinal SlgA and Th1/Th17 cellular responses to encapsulated antigens following oral vaccination [155]. Glucan microparticles target enterocytes and M cells for uptake and activate them to secrete and express cytokines and β-glucan receptors [154–156]. β-Glucans, the major component of glucan microparticles, are fungal PAMPs, signaling through receptors such as dectin-1 and complement receptor 3 expressed on DCs, monocytes, and neutrophils [153,157]. Although the efficacy of glucan particles as an oral vaccine carrier was well proved with model antigens such as OVA or BSA, the application to pathogenic microorganisms has been relatively rare [158]. One reason for the limited use of glucan particles is that their manufacture is currently limited to liquid formulations, which require cold-chain storage and therefore are not optimal for the use in poorer regions [79].

VIII. ORAL DELIVERY OF VACCINES USING FOOD MATERIALS

Plant-based oral vaccines have advantages over the traditional vaccines in cost, safety, and scalability. Since 1990, researchers have manufactured edible plant-based vaccines in carrot, soybean, tomato, rice, potato, and tobacco against microbial pathogen antigens such as the heat-labile toxin B subunit (LTB) of enterotoxigenic Escherichia coli, cholera toxin B subunit (CTB), and antigens from Yersinia pestis and viruses, such as hepatitis B virus, rotavirus, and Norwalk virus [159]. Many conventional vaccines are not widely distributed in developing
countries where those vaccines are urgently needed, because of high production costs and the requirement of better infrastructure. One more problem standing in the way of wider distribution of desperately needed vaccines is that the conventional cell fermentation systems for producing recombinant protein vaccine antigens are often expensive and are not easily scalable [160]. Another emerging infectious disease field is One Health, dealing with zoonotic diseases spreading in both animals and humans. A solution to this may be the use of plants or plant cells as bioreactors. Molecular farming has become well established for the production of vaccines, and many proofs of principle and important proofs of efficacy are accumulating continuously [161]. MucoRice should be one of the most innovative approaches for oral vaccine delivery using edible rice as a carrier (Chapter 20: Plant-Based Mucosal Vaccine Delivery Systems). Rice seeds have stability and resistance to digestion in the stomach, making MucoRice an attractive oral vaccine delivery system. In 2007, it was first reported that cholera toxin B subunit (CTB) could be expressed in the rice seed. As much as 30 μg of CTB per seed was stored in the storage organelle protein body. When orally ingested, rice seeds expressing CTB induced CTB-specific serum IgG and mucosal IgA antibodies with neutralizing activity, while no rice storage-specific immune response was noted. When expressed in rice, CTB was protected from pepsin digestion in vitro [162]. Rice-expressed CTB also remained stable and thus maintained immunogenicity at room temperature for more than 3 years, and it provided more than 6 months of protection against CT- or LT-induced diarrhea after primary immunization [163]. These results show that the MucoRice vaccine could be stockpiled longer at room temperature and could be widely used for oral vaccination without cold-chain management. Rice-based oral vaccine developments are under way against many infectious diseases and noninfectious diseases such as allergy, autoimmunity, and Alzheimer’s disease [159].

A. Tablets and Capsules

The most widely used form of whole bacterial cell vaccines for cholera and typhoid fever was liquid suspension. Because of the lack of shelf stability, the liquid format is unsuitable for storage and distribution in developing countries. In this regard, a stable solid dosage vaccine platform is required for those vaccines. Formulation in tablets or capsules would provide more stability and ease of handling. In comparison to microparticles and NPs, capsules are significantly larger in size and could serve reservoir for multiple vaccine/adjuvant formulations [79]. While no subunit or WC killed oral vaccine is currently delivered by capsule or tablet, the live attenuated Salmonella vaccine Vivotif is routinely delivered in an enteric-coated format [164]. Capsules could be manufactured in appropriate physical sizes (the average size of capsules and tablets ranges from 5 to 20 mm) suitable for administration to target populations. With enteric coatings, tablets and capsules could be protected from gastric acid and endowed with controlled release properties, which will provide facilitated delivery to discrete locations in the intestine. In principle, capsules allow the incorporation of many previously introduced delivery technologies in one primary delivery format. Recently, a tablet-based oral avian influenza vaccine was shown to elicit strong antiviral antibody and IFN-γ T-cell responses. This approach utilized a nonreplicating adenovirus type 5 vector expressing avian flu hemagglutinin antigens together with a dsRNA TLR3 agonist [165].

B. Nasal Vaccine Delivery

Among the choices of mucosal routes for vaccine administration, nasal delivery has been the most widely employed for innovative research because of the ease of approach and less harsh physicochemical conditions in the nasal cavity compared with the GI tract.
Furthermore, nasal vaccines could be administered without professional training. There are at least three nasal vaccines licensed worldwide. The FDA approved FluMist, a live attenuated trivalent/quadrivalent influenza vaccine. Fluenz is an EMA-approved quadrivalent influenza vaccine. These two intranasal vaccines are manufactured by the same company, MedImmune. The Serum Institute of India licensed the monovalent NasoVac against pandemic A/California/7/2009 H1N1 influenza (Chapter 39: Nasal Influenza Vaccines).

Besides influenza vaccines, the nasal route has been widely studied for development of many prophylactic and therapeutic vaccines against other infectious diseases, such as allergy, cancer, Alzheimer’s disease, and lifestyle-related diseases [166–169]. The human nasal cavity is an attractive route of mucosal immunization, having a total surface area of 150 cm² with a volume of 15–20 mL [52,170,171]. The nasal cavity is divided into five anatomical and functional regions: the nasal vestibule, the atrium, the respiratory region, the olfactory region, and the nasopharynx [171]. The respiratory region is where nasal delivery of drugs and vaccines occurs, since it is the most permeable region, having a large surface area and a rich vascular bed [172]. The respiratory region is covered by a pseudostratified epithelium composed of columnar cells interspersed with goblet cells, which are interconnected by tight junctions (zonae occludens). The tight junctions are relatively resistant to paracellular passages of particulate materials in the breathed air [173]. The respiratory region is where mucus production actively takes place. The mucus layer in the nasal tract is relatively thinner (5 μm) than other mucosal surfaces. The nasal cavity is equipped with nasopharyngeal-associated lymphoid tissue (NALT), which is highly similar to Peyer’s patches in the ileum [174]. NALT is also covered with M cells that have active antigen sampling capacity [175]. Intraepithelial DCs project dendrites toward mucosal lumen and sample antigens. Particulate antigens are preferentially sampled by M cells, and small soluble antigens have access to epithelium, where they are captured by intraepithelial DCs [173] (Chapter 2: Anatomical Uniqueness of the Mucosal Immune System (GALT, NALT, iBALT) for the Induction and Regulation of Mucosal Immunity and Tolerance).

The mucociliary clearance mechanism should have negative effects on nasal vaccination. The rapid turnover of mucus (10–15 minutes) and fast mucus flow (~5 mm/min) in the nasal cavity limit the length of residence of administered vaccine. Continuous outward movement of cilia on the epithelial apical surface accelerates the clearance of mucus-trapped substances. To make matters worse, nasal enzymes and local pH negatively affect the stability of nasally administered vaccine antigens [170]. This could be why only live attenuated influenza vaccines proved effective in clinical trials and were approved by the FDA and EMA. A live influenza virus should be able to survive in the nasal mucosa and be harnessed with built-in adjuvants. An inactivated split influenza vaccine was also tested for nasal delivery but proved ineffective without coformulation with appropriate mucosal adjuvants [176–178]. To achieve equivalent antibody responses without adjuvant, an inactivated split antigen should be given at least three times more, or an inactivated whole virus should have been immunized [179–181]. Given that even an inactivated virus antigen requires potent mucosal adjuvants to achieve optimal immune responses in the systemic and mucosal compartments, protein antigens should employ even stronger mucosal adjuvants to be effective by nasal vaccination. Many mucosal adjuvants are suggested as formulation partners of nasal vaccine antigens [182,183].

CT and related E. coli heat-labile toxin (LT) and their mutant derivatives are the most widely tried mucosal adjuvant in preclinical studies [167]. Although those enterotoxins served as potent adjuvants for nasal vaccination of diverse antigens in animal studies, they
have seldom been adopted for the development of human nasal vaccines. The use of enterotoxins as nasal vaccine adjuvants has a very serious failure history. The subunit influenza nasal vaccine Nasalflu Berna adjuvanted with E. coli LT had been significantly connected with Bell’s palsy with an odd ratio of 84 in an epidemiological study in Switzerland. The vaccine was consequently withdrawn from the market [184]. The adverse effect could be related with the capacity of LTB and CTB subunit to bind to GM1 ganglioside expressed on neuronal cell and retrograde translocation toward the brain [185,186]. Since the nasal cavity and brain are separated by a thin anatomical structure and are directly connected by the olfactory nerve, binding of any vaccine component to the olfactory nerve should contribute neurotoxicity. In this context, any nasal vaccine, adjuvant, or delivery system must clear the safety concern to be introduced to the market. Given the versatility and ease of nasal vaccination, numerous research groups are studying safe nasal adjuvants that could replace CT and LT. PAMPs are most widely studied as alternative nasal adjuvants. Recently published literature shows that ligands of TLR2, TLR5, and TLR9, STING agonist, and Flt3 ligand could be used as effective and safe nasal adjuvants [177,187–190].

Vaccine antigens should remain sufficiently stable in the nasal mucosa and should be able to reach to antigen-capturing cells surviving the mucociliary clearance mechanism. To overcome those hurdles, micro/nanocarriers for nasal vaccine delivery have been actively researched. To increase the residence time at mucosal surfaces, several strategies have been developed to increase adhesiveness of antigen delivery systems to the nasal mucus [191,192]. However, the mucus is not a static barrier; it is continuously secreted and cleared from the nasal cavity by the cilia beating on columnar epithelial cells. Mucoadhesion ability of delivery carrier would cause earlier removal of vaccine antigens when mucociliary clearance mechanism is intact. To cope with this problem, nasal vaccine carriers should cross the mucus layer rapidly and deliver antigens to M cells and DCs rather than strongly adhering to it [193–195]. Strategies that prevent vaccine carrier–mucus interactions and hence allow for free diffusion by mucopenetration should be more effective in inducing efficacious immune responses [196]. However, many reports claimed that mucoadhesive NPs effectively enhanced the efficacy of mucosal vaccines [192]. One study showed that mucoadhesive NPs disrupted the protective human mucus barrier by altering its microstructure [197]. The disrupted microstructure resulted in a 20% increase in mucus mesh pore size. This disrupted mucus mesh would allow increased passage of other NPs to reach to the epithelium.

1. Advantages and Limitations of Nasal Vaccines

The comparative advantages and disadvantages of intranasal vaccination are summarized in Table 19.3. The most outstanding advantage is the ease of administration, while the safety issue is the most essential problem to be resolved.

2. Nasal Vaccine Delivery Systems

A. NANOEMULSIONS

Nanoemulsions, owing to their stability, small droplet size, and optimal solubilization properties, have great potential in nasal drug delivery. Furthermore, they may act as an active adjuvant in nasal vaccine formulations. Despite the promising results of in vitro and animal studies, the application of nanoemulsions for nasal delivery in humans appears to be hindered mainly by the lack of detailed toxicology studies and the lack of extensive clinical trials [198]. A cationic nanoemulsion formulation could have facilitated cellular uptake of model antigen ovalbumin in the nasal epithelial cell line [199]. The intranasal vaccination of HIV gp120 immunogen formulated in oil-in-water nanoemulsions induced robust serum
anti-gp120 IgG and Th1-polarized systemic cellular immune responses [200].

IX. LIPOSOMES

A large number of studies have investigated the potential of liposomes as a delivery system for nasal vaccination. Those liposome formulation vaccines targeted diverse pathogens: viruses (influenza, human immunodeficiency virus [HIV], lymphocytic choriomeningitis virus, hepatitis B virus, respiratory syncytial virus, Newcastle disease virus) and bacteria (*Mycobacterium tuberculosis*, *V. cholerae*, *Pseudomonas aeruginosa*, *Y. pestis*, *Actinobacillus pleuropneumoniae*) [201]. Peptides, proteins, and DNA can be successfully carried by liposomes having neutral, negative, and positive charges. Cationic liposomes were shown to interact more efficiently with epithelial cells and DCs [202,203].

Induction of cell-mediated immunity is another important feature of liposome-mediated adjuvanticity [204]. Intranasal administration of DNA vaccine formulated with cationic liposomes, together with IL-12- and/or GM-CSF-expressing plasmids, resulted in both high levels of HIV-1-neutralizing antibodies in feces and serum and high levels of HIV-specific CTL responses [205]. Using this characteristic of the liposomal delivery system, a successful anti-tumor cellular immune response could be induced by intranasal immunization of DC-targeting liposomes carrying a tumor antigen [206]. Similarly, intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicited both mucosal cell-mediated and humoral (IgA and IgG) immune responses [207].

X. CHITOSAN

Intranasal chitosan solution formulations were reported to enhance protective immune responses against many antigens, including diphtheria, pertussis, and influenza [208–210]. Chitosan solutions seem to induce balanced Th1 and Th2 responses with neutralizing antibodies [211]. Whole influenza virus formulated with trimethylated chitosan showed much closer interaction with the epithelial surface, with the potential to generate enhanced uptake and induction of immune responses with minimal local toxicity in terms of ciliary beat frequency in the nasal cavity [212]. Chitosan dry power in salt form enables a thermally stable vaccine formulation that does not require cold chains. Chitosan power formulations were shown to outperform solutions in eliciting humoral responses against diphtheria, anthrax, and norovirus [213].

Chitosan microparticles and NPs are being robustly studied for the intranasal delivery of vaccines. Chitosan particles are basically mucoadhesive and able to deliver adjuvants and antigen cargos to efficiently promote humoral and cellular immune responses. Protein and peptide antigen-loaded chitosan particles are taken up by APCs in the administration site and eventually trafficked to draining lymph nodes, where T-cell activation occurs [39]. To be used for better intranasal delivery, chitosan should be chemically modified for better solubility, stability, mucoadhesiveness, safety, and resilience against degradation [214]. Chitosan itself shows strong adhesion to mucosal surfaces, providing a longer retention time at the nasal mucosa, and disrupts the tight junctions between nasal epithelial cells, which leads to enhanced paracellular transport of antigens [167]. The paracellular transport of the vaccine formulation into the nasal mucosa would lead to enhanced antigen uptake and presentation by APCs, with consequently augmented adaptive immunity [215]. This was demonstrated in a subunit influenza vaccine study showing protection against a heterologous viral challenge [216]. N-trimethyl chitosan nasal vaccine formulation
was superior to PLGA NPs in inducing nasal IgA responses [217]. Improved mucosal (IgA) and humoral (IgG) antibody responses are generally observed in mice as well as in other animal models such as rat and rabbit [218]. The cationic chitosan enhanced Th1 and Th17 responses as well as DC maturation through type I interferon induction by the cGAS-STING pathway, suggesting the involvement of multiple immune components [219].

Modified chitosan particles were generated to improve delivery efficiency and targeting. PEGylation improved water solubility and stability of conjugated antigens [37]. Chitosan coated poly-(ε-caprolactone) NPs induced enhanced mucosal immune responses against coformulated influenza antigen [220]. Protein antigen-loaded Pluronic F-127/chitosan microparticles showed improved antigen release and induced higher antigen-specific secretory IgA responses after intranasal vaccination [221]. OVA-loaded trimethyl chitosan–hyaluronic acid NPs demonstrated superior immunogenicity after intranasal immunization [222]. Mannosylation of chitosan particles enhanced macrophage targeting and antigen-specific secretory IgA responses in mucosal secretions after intranasal immunization [223].

Chitosan application to intranasal vaccination has already reached clinical trial stages (phases 2 and 3) in the form of NPs [224] and antigen-conjugates [225]. Norovirus VLP formulated with MPLA was administered intranasally twice to healthy volunteers, inducing specific IgA responses in 70% of vaccinated individuals [224]. A clinical study testing intranasal vaccination of Neisseria meningitidis serogroup C polysaccharide (MCP)-CRM197 conjugate antigen mixed with chitosan showed specific IgA responses in nasal washes and balanced IgG1/IgG2 responses in serum [225]. Despite several clinical studies with promising results, no chitosan-based product for intranasal vaccination has yet reached the market.

XI. STARCH NANOPARTICLES

Influenza viral antigens encapsulated within bioadhesive starch and propylacrylic acid mixtures induced significant systemic antigen-specific IgG responses but not mucosal IgA after intranasal delivery of the influenza vaccine in rabbit [226]. Inactivated influenza antigens in positively charged NPs have been tested in a phase 1 clinical study. Significant mucosal IgA antibodies were produced in individuals who received two-dose nasal immunizations [227]. A cationic maltodextrin NP (cationic surface with an anionic lipid core) showed longer nasal residence time after nasal administration than liposomes and PLGA NPs [228].

XII. POLYMER NANOPARTICLES

The PLGA NPs are the most used synthetic polymer for nasal vaccine delivery studies. Cationic modification of PLGA enhanced residence time in the mucosa and resulted in better immune responses with higher serum antibody and SIgA levels [217]. The surface modification of PLGA carriers with chitosan can increase mucoadhesion through a change of zeta potential from negative to positive without affecting particle size and dispersion. Moreover, the clearance rate in the nasal cavity was reduced, resulting in enhanced systemic and mucosal antibody responses [229]. Many antigens encapsulated in PLGA nano/microparticles were immunized through the nasal route to show enhanced immune responses in both systemic and mucosal immune compartments; they were ovalbumin, bovine serum albumin, bovine parainfluenza virus, bovine syncytial virus, HBsAg, malaria, swine fever virus, Y. pestis, and Streptococcus equi [230]. Targeting efficiency to M cells could also be achieved by functionalization of the particle surface [19].
XIII. NANOGELS

Although many types of nanogels were tested as vaccine delivery systems, the cholesteryl group-bearing pullulan (CHP) is the most extensively studied one for mucosal vaccine delivery [6]. The cationic CHP (cCHP) nanogel binds better to epithelial cells and is subsequently taken up with high efficiency into the cells. The cCHP nanogel itself did not activate DCs and did not have biologically active adjuvant activity. However, vigorous neutralizing serum IgG and SIgA responses were noted without coadministration of mucosal adjuvants. The cCHP nanogel was suggested as a universal protein-based antigen delivery vehicle for adjuvant-free intranasal vaccinations [51] (Chapter 26: Nanodelivery Vehicles for Mucosal Vaccines). To further potentiate immune responses against cargo antigens, cytokines or adjuvant could be coencapsulated in the CHP nanogel. TNFα encapsulated in the nanogel acted as a vaccine adjuvant for a nasal influenza vaccine [231]. In an antiobesity vaccine study, cCHP was engineered to carry the adjuvant cyclic di-GMP along with self-origin antigen ghrelin peptide hormone conjugated to a carrier protein PspA [166,169]. The cCHP-based nasal vaccines were successfully tested for use against several infectious diseases and lifestyle-related diseases: influenza, Streptococcus pneumoniae, C. botulinum, obesity, and hypertension [51,63,166,168,169,232]. Another very promising virtue of the cCHP nanogel nasal delivery system is safety. It was shown reiterately that protein antigens carried by the nanogel did not accumulate in the olfactory bulb and brain, thus excluding the risk of neurotoxicity or brain damage [51,232]. When all the physicochemical, biological, and immunological characteristics are considered, the cCHP nanogel platform seems to be the most promising nasal delivery system to be translated into more aggressive clinical applications.

XIV. CONCLUDING REMARKS AND FUTURE PERSPECTIVES

Although mucosal vaccination has many advantages, a very limited number of mucosal vaccines have been licensed. The most widely tested vaccination routes are oral and intranasal. Currently licensed oral and intranasal vaccines are composed predominantly of WC killed or live attenuated microorganisms, where cell bodies serve as delivery systems and whose cell components act as built-in adjuvants. Future mucosal vaccines should be made with more purified antigen components, which will require safe and efficacious adjuvants and delivery systems. Recent developments in biomaterials and nanotechnology have enabled many innovative mucosal vaccine trials. For oral vaccination, the vaccine delivery system should be able to stably carry antigens and adjuvants and resist the harsh physicochemical conditions in the stomach and intestinal tract. Besides many nano/microcarrier tools generated by using natural and chemical materials, the development of oral vaccine delivery systems using food materials should be more robustly researched to expand vaccine coverage of GI infections in developing countries. For intranasal vaccination, the vaccine delivery system should survive the very active mucociliary clearance mechanisms and provide safety, given the anatomical location of the nasal cavity, which is separated from the central nervous system by a thin barrier. Future mucosal vaccine carriers, regardless of administration routes, should share common characteristics. They should maintain stability in given environments, be mucoadhesive, and have targeting ability to specific tissues and cells.

References

[1] Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P T 2017;42(12):742–55.
[2] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res 2016;33 (10):2373–87.
[3] Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008;60 (8):915–28.
[4] Di Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel) 2015;3(2):320–43.
[5] Garcia A, Lema D. An updated review of ISCOMSTM and ISCOMATRIXTM vaccines. Curr Pharm Des 2016;22(41):6294–9.
[6] Nakahashi-Ouchida R, Yuki Y, Kiyono H. Development of a nanogel-based nasal vaccine as a novel antigen delivery system. Expert Rev Vaccines 2017;16(12):1231–40.
[7] Eskandari S, Guerin T, Toth I, Stephenson RJ. Recent advances in self-assembled peptides: implications for targeted drug delivery and vaccine engineering. Adv Drug Deliv Rev 2017;110–111:169–87.
[8] Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 2013;3:13.
[9] Peres C, Matos AI, Conniot J, Sainz V, Zupancic E, Silva JM, et al. Poly(lactic acid)-based particulate systems are promising tools for immune modulation. Acta Biomater 2017;71:484–57.
[10] Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 2009;14(9):3286–312.
[11] Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 2013;12(7):747–58.
[12] Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008;26 (26):3209–22.
[13] Garcon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an adjuvant system containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012;11 (3):349–66.
[14] Misquith A, Fung HW, Dowling QM, Gudерian JA, Vedvick TS, Fox CB. In vitro evaluation of TLR4 agonist activity: formulation effects. Colloids Surf B Biointerfaces 2014;113:312–19.
[15] Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a stable and potent adjuvant for human vaccines. Pharm Biotechnol 1995;6:277–96.
[16] Cox JC, Sjolander A, Barr IG. ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 1998;32 (3):247–71.
[16a] De Serrano LO, Burkhart DJ. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines. J Nanobiotechnol 2017;15 (1):83.
[17] Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 2010;6(1):9–24.
[18] Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55(3):329–47.
[19] Allahyari M, Mohit E. Peptide/protein vaccine delivery system based on PLGA particles. Hum Vaccin Immunother 2016;12(3):806–28.
[20] Wendorf J, Singh M, Chesko J, Kazzaz J, Soewanan E, Ugozzoli M, et al. A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci 2006;95 (12):2738–50.
[21] Jain S, O’Hagan DT, Singh M. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines 2011;10(12):1731–42.
[22] Johansen P, Men Y, Merkle HP, Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 2000;50(1):129–46.
[23] Crotts G, Park TG. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. J Microencapsul 1998;15 (6):699–713.
[24] Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008;38(5):1404–13.
[25] Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010;10(11):787–96.
[26] Lasprilla AJ, Martinez GA, Lunelli BH, Jardini AL, Filho RM. Poly-lactic acid synthesis for application in biomedical devices – a review. Biotechnol Adv 2012;30(1):321–8.
[27] Lee BK, Yun Y, Park K. PLA micro- and nano-particles. Adv Drug Deliv Rev 2016;107:176–91.
[28] Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996;17(2):93–102.
[29] Danhier F, Ansoere A, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012;161 (2):505–22.
[30] Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 2008;125(3):193–209.

IV. CURRENT AND NEW APPROACHES FOR MUCOSAL VACCINE DELIVERY

REFERENCES

[30] Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 2008;125(3):193–209.
19. CURRENT AND NEW APPROACHES FOR MUCOSAL VACCINE DELIVERY

[31] Giteau A, Venier-Julienne MC, Aubert-Pouessel A, Benoit JP. How to achieve sustained and complete protein release from PLGA-based microparticles? Int J Pharm 2008;350(1–2):14–26.

[32] Mohammadi-Samani S, Taghipour B. PLGA micro and nanoparticles in delivery of peptides and proteins: problems and approaches. Pharm Dev Technol 2015;20(4):385–93.

[33] Johansen P, Men Y, Audran R, Corradin G, Merkle HP, Gander B. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm Res 1998;15(7):1103–10.

[34] Silva AL, Rosalia RA, Sazak A, Carstens MG, Ossendorp F, Oostendorp J, et al. Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation. Eur J Pharm Biopharm 2013;83(3):338–45.

[35] Dang JM, Leong KW. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev 2006;58(4):487–99.

[36] Leleux J, Roy K. Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective. Adv Healthc Mater 2013;2(5):72–94.

[37] Singh B, Maharjan S, Cho KH, Cui L, Park IK, Choi YJ, et al. Chitosan-based particulate systems for the delivery of mucosal vaccines against infectious diseases. Int J Biol Macromol 2018;110:54–64.

[38] Thanou M, Florea BI, Langemeyer MW, Verhoef JC, Junginger HE. N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug busulfolin in vitro (Caco-2 cells) and in vivo (rats). Pharm Res 2000;17(1):27–31.

[39] Chua BY, Al Kobaisi M, Zeng W, Mainwaring D, Jackson DC. Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunococontraceptive vaccines. Mol Pharm 2012;9(1):81–90.

[40] Sayin B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci 2009;38(4):362–9.

[41] Wee S, Gombotz WR. Protein release from alginate matrices. Adv Drug Deliv Rev 1998;31(3):267–85.

[42] Hori Y, Winans AM, Irvine DJ. Modular injectable matrices based on alginate solution/microsphere mixtures that gel in situ and co-deliver immunomodulatory factors. Acta Biomater 2009;5(4):969–82.

[43] Yang D, Jones KS. Effect of alginate on innate immune activation of macrophages. J Biomed Mater Res A 2009;90(2):411–18.

[44] McCarthy RE, Arnold LW, Babcock GF. Dextran sulphate: an adjuvant for cell-mediated immune responses. Immunology 1977;32(6):963–74.

[45] de Geest BG, Willart MA, Lambrecht BN, Pollard C, Vervaet C, Remon JP, et al. Surface-engineered poly-electrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function. Angew Chem Int Ed Engl 2012;51(16):3862–6.

[46] Rad-Malekshahi M, Lempsink L, Amid M, Hennink WE, Mastrobattista E. Biomedical applications of self-assembling peptides. Bioconjug Chem 2016;27(1):3–18.

[47] Rudra JS, Tian YF, Jung JP, Collier JH. A self-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci U S A 2010;107(2):622–7.

[48] Rudra JS, Sun T, Bird KC, Daniels MD, Gasiorowski JZ, Chong AS, et al. Modulating adaptive immune responses to peptide self-assemblys. ACS Nano 2012;6(2):1557–64.

[49] Chen JJ, Pompano RR, Santiago FW, Maillat L, Sciammas R, Sun T, et al. The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials 2013;34(34):8776–85.

[50] Zarekar NS, Lingayat VJ, Pande VV. Nanogel as a novel platform for smart drug delivery system. Nanosci Nanotechnol Res 2017;4(1):25–31.

[51] Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T, et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 2010;9(7):572–8.

[52] Salatín S, Barar J, Barzegar-Jalali M, Adibkia K, Milani MA, Jelvehgari M. Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery. Arch Pharm Res 2016;39(9):1181–92.

[53] Zhang T, Yang R, Yang S, Guan J, Zhang D, Ma Y, et al. Research progress of self-assembled nanogel and hybrid hydrogel systems based on pullulan derivatives. Drug Deliv 2018;25(1):278–92.

[54] Sasaki Y, Akiyoshi K. Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. Chem Rec 2010;10(6):366–76.

[55] Kimoto T, Shibuya T, Shiobara S. Safety studies of a novel starch, pullulan: chronic toxicity in rats and bacterial mutagenicity. Food Chem Toxicol 1997;35(3–4):323–9.

[56] Ferreira SA, Coutinho PJG, Gama FM. Synthesis and characterization of self-assembled nanogels made of pullulan. Materials (Basel) 2011;4(4):601–20.

[57] Akiyoshi K, Deguchi S, Moriguchi N, Yamaguchi S, Sunamoto J. Self-aggregates of hydrophobized polysaccharides in water. Formation and characteristics of nanoparticles. Macromolecules 1993;26(12):3062–8.
REFERENCES

[58] Shimizu T, Kishida T, Hasegawa U, Ueda Y, Imanishi J, Yamagishi H, et al. Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy. Biochem Biophys Res Commun 2008;367(2):330–5.

[59] Yuki Y, Nochi T, Kong IG, Takahashi H, Sawada S, Akiyoshi K, et al. Nanogel-based antigen-delivery system for nasal vaccines. Biotechnol Genet Eng Rev 2013;29:61–72.

[60] Asayama W, Sawada S, Taguchi H, Akiyoshi K. Comparison of refolding activities between nanogel artificial chaperone and GroEL systems. Int J Biol Macromol 2008;42(3):241–6.

[61] Nomura Y, Ikeda M, Yamaguchi N, Aoyama Y, Akiyoshi K. Protein refolding assisted by self-assembled nanogels as novel artificial molecular chaperone. FEBS Lett 2003;553(3):271–6.

[62] Ayame H, Morimoto N, Akiyoshi K. Self-assembled cationic nanogels for intracellular protein delivery. Bioconj Chem 2008;19(4):882–90.

[63] Kong IG, Sato A, Yuki Y, Nochi T, Takahashi H, Sawada S, et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun 2013;81(5):1625–34.

[64] Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012;12(8):592–605.

[65] Date KA, Vicari A, Hyde TB, Mintz E, Danovaro-Holliday MC, Henry A, et al. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010–2011. Emerg Infect Dis 2011;17(11):2105–12.

[66] Mantis NJ, Morici LA, Roy CJ. Mucosal vaccines for biodefense. Curr Top Microbiol Immunol 2012;354:181–95.

[67] Marasini N, Skwarczynski M, Toth I. Oral delivery of nanoparticle-based vaccines. Expert Rev Vaccines 2014;13(11):1361–76.

[68] Modlin J, Wenger J. Achieving and maintaining polio eradication—new strategies. N Engl J Med 2014;371(16):1476–9.

[69] Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992;14(2):568–79.

[70] Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010;8:129.

[71] Alcock R, Cottingham MG, Rollier CS, Furze J, De Costa SD, Hanlon M, et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiologica temperaturess in carbohydrate glass. Sci Transl Med 2010;2(19):19ra12.

[72] Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M. PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Rev Vaccines 2017;16(3):197–213.

[73] Sow SO, Tapia MD, Chen WH, Haidara FC, Kotloff KL, Pasetti MF, et al. A randomized, placebo-controlled, double-blind Phase 2 trial comparing the reactogenicity and immunogenicity of a single ≥2x10⁸ colony forming units [cfu] standard-dose versus a ≥2x10⁹ cfu high-dose of CVD 103-HgR live attenuated oral cholera vaccine, with Shanchol inactivated oral vaccine as an open label immunologic comparator. Clin Vaccine Immunol 2017;. Available from: https://doi.org/10.1128/CVI.00265-17.

[74] Cabrera A, Lepage JE, Sullivan KM, Seed SM. Vaxchora: a single-dose oral cholera vaccine. Ann Pharmacother 2017;51(7):584–9.

[75] Ge W, Hu PZ, Huang Y, Wang XM, Zhang XM, Sun YJ, et al. The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following different administration routes. Oncol Rep 2009;22(4):915–20.

[76] Ge W, Li Y, Li ZS, Zhang SH, Sun YJ, Hu PZ, et al. The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route. Cancer Immunol Immunother 2009;58(2):201–8.

[77] Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001;47(1):113–31.

[78] Yang Y, Kuang Y, Liu Y, Li W, Jiang Z, Xiao L, et al. Immunogenicity of multiple-epitope antigen gene of HCV carried by novel biodegradable polymers. Comp Immunol Microbiol Infect Dis 2011;34(1):65–72.

[79] Davitt CJ, Lavelle EC. Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliv Rev 2015;91:52–69.

[80] Silva AC, Santos D, Ferreira D, Lopes CM. Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes. Curr Med Chem 2012;19(26):4495–510.

[81] Zho F, Neutra MR. Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier. Biosci Rep 2002;22(2):355–69.

[82] Parmentier J, Thomas N, Mullertz A, Fricker G, Rades T. Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis. Int J Pharm 2012;437(1–2):253–63.

[83] Chauhan MK, Sahoo PK, Rawat AS, Singh A, Bamrara A, Sharma D. Bilosomes: a novel approach to meet the challenges in oral immunization. Recent Pat Drug Deliv Formul 2015;9(3):201–12.
[84] Jacobsen AC, Jensen SM, Fricker G, Brandl M, Treusch AH. Archaeal lipids in oral delivery of therapeutic peptides. Eur J Pharm Sci 2017;108:101–10.

[85] Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, Nakagawa S, et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Control Release 1999;61(1–2):233–40.

[86] Christensen D, Korsholm KS, Rosenkranz I, Lindenstrom T, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2007;6(5):785–96.

[87] Wei X, Shao B, He Z, Ye T, Luo M, Sang Y, et al. Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response. Cell Res 2015;25(2):237–53.

[88] Nguyen TX, Huang L, Gauthier M, Yang G, Wang Q. Recent advances in liposome surface modification for oral drug delivery. Nanomedicine (Lond) 2016;11(9):1169–85.

[89] Venkatesan N, Vyas SP. Polysaccharide coated liposomes for oral immunization – development and characterization. Int J Pharm 2000;203(1–2):169–77.

[90] Chen H, Torchilin V, Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm Res 1996;13(9):1378–83.

[91] Souza M, Costantini V, Azevedo MS, Saif LJ. A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine 2007;25(50):8448–59.

[92] Aguila A, Donachie AM, Peyre M, McSharry CP, Sesardic D, Mowat AM. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine. Vaccine 2006;24(24):5201–10.

[93] Eliaisson DG, Helgeby A, Schon K, Nygren C, El-Bakkouri K, Fiers W, et al. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine 2011;29(23):3951–61.

[94] Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillen G, Aguilar JC. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol 2005;42(3):289–94.

[95] Nguyen TV, Yuan L, Azevedo MS, Jeong KI, Gonzalez AM, Iosef C, et al. High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen. Clin Vaccine Immunol 2006;13(4):475–85.

[96] Azevedo MS, Gonzalez AM, Yuan L, Jeong KI, Iosef C, Van Nguyen T, et al. An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model. Clin Vaccine Immunol 2010;17(3):420–8.

[97] Jariyapong P, Xing L, van Houten NE, Li TC, Weerachatyanukul W, Hsieh B, et al. Chimeric hepatitis E virus-like particle as a carrier for oral delivery. Vaccine 2013;31(2):417–24.

[98] Kuate Defo Z, Lee B. New approaches in oral rotavirus vaccines. Crit Rev Microbiol 2016;42(3):495–505.

[99] Nerome K, Matsuda S, Maegawa K, Sugita S, Kuroda K, Kawasaki K, et al. Quantitative analysis of the yield of avian H7 influenza virus haemagglutinin protein produced in silkworm pupae with the use of the codon-optimized DNA: a possible oral vaccine. Vaccine 2017;35(5):738–46.

[100] Shuttleworth G, Eckery DC, Awram P. Oral and intraperitoneal immunization with rotavirus 2/6 virus-like particles stimulates a systemic and mucosal immune response in mice. Arch Virol 2005;150(2):341–9.

[101] Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003;108(3):241–7.

[102] Zhai Y, Zhong Z, Zariffard M, Spear GT, Qiao L. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies. Vaccine 2013;31(46):5422–9.

[103] Czyz M, Dembczynski R, Marecik R, Wojas-Turek J, Milczarek M, Pajtasz-Piasecka E, et al. Freeze-drying of plant tissue containing HBV surface antigen for the oral vaccine against hepatitis B. Biomed Res Int 2014;2014:485689.

[104] Huang Y, Fayad R, Smock A, Ullrich AM, Qiao L. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine. Cancer Res 2005;65(15):6990–9.

[105] Scotti N, Rybicki EP. Virus-like particles produced in plants as potential vaccines. Expert Rev Vaccines 2013;12(2):211–24.

[106] Chen Q, Lai H. Plant-derived virus-like particles as vaccines. Hum Vaccin Immunother 2013;9(1):26–49.

[107] Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 2008;26(15):1846–54.
REFERENCES

[108] Warzecha H, Mason HS, Lane C, Tryggvesson A, Rybicki E, Williamson AL, et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003;77(16):8702–11.

[109] Zhang X, Buehner NA, Hutson AM, Estes MK, Mason HS. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol J 2006;4(4):419–32.

[110] Huang Z, Elkin G, Maloney BJ, Beuhrn N, Arntzen CJ, Thanavala Y, et al. Virus-like particle particle and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 2005;23(15):1851–8.

[111] des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006;116(1):1–27.

[112] Wang T, Zou M, Jiang H, Ji Z, Gao P, Cheng G. Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. Eur J Pharm Sci 2011;44 (5):653–9.

[113] Garinot M, Fievez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L, et al. PE-Gated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 2007;120(3):195–204.

[114] Primard C, Rochereau N, Luciani E, Genin C, Delair T, Paul S, et al. Traffic of poly(lactic acid) nanoparticle vaccine vehicle from intestinal mucus to subepithelial immune competent cells. Biomaterials 2010;31(23):6060–8.

[115] Brayden DJ, Baird AW. Microparticle vaccine approaches to stimulate mucosal immunisation. Microbes Infect 2001;3(10):867–76.

[116] Wischke C, Borchert HH, Zimmermann J, Siebenbrodt I, Lorenzen DR. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release 2006;114(3):359–68.

[117] Castellanos IJ, Crespo R, Grieben K. Poly(ethylene glycol) as stabilizer and emulsifying agent: a novel stabilization approach preventing aggregation and inactivation of proteins upon encapsulation in biodegradable polyester microspheres. J Control Release 2003;88(1):135–45.

[118] Fischer S, Uetz-von Allmen E, Waechterle-Men Y, Groettrup M, Merkle HP, Gander B. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 2007;28(6):994–1004.

[119] Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 2000;50(1):147–60.

[120] Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000;21(23):2475–90.

[121] Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC, et al. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitocrural viral infection. Nat Med 2012;18(8):1291–6.

[122] Reyes-Ortega F, Rodriguez G, Aguilar MR, Lord M, Whitelock J, Stenzel MH, et al. Encapsulation of low molecular weight heparin (bemiparin) into polymeric nanoparticles obtained from cationic block copolymers: properties and cell activity. J Mater Chem B 2013;1(6):850–60.

[123] Zhang L, Zeng ZZ, Hu CH, Bellis SL, Yang WD, Su YT, et al. Controlled and targeted release of antigens by intelligent shell for improving applicability of oral vaccines. Biomaterials 2010;31(7):2365–8.

[124] Tan Z, Liu W, Li C, Zhang Y, Meng X, et al. Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection. Eur J Pharm Biopharm 2017;111:33–43.

[125] Mishra N, Tiwari S, Vaidya B, Agrawal GP, Vyas SP. Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B. J Drug Target 2011;19(1):67–78.

[126] Du L, Yu Z, Pang F, Xu X, Mao A, Yuan W, et al. Targeted delivery of GP5 antigen of PRRSV to M cells enhances the antigen-specific systemic and mucosal immune responses. Front Cell Infect Microbiol 2018;8:7.

[127] Fievez V, Plapied L, des Rieux A, Pourcelle V, Freichels H, Wascotte V, et al. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm 2009;73(1):16–24.

[128] Peter Y, Goodenough D. Claudins. Curr Biol 2004;14 (8):R293–4.

[129] Jiang T, Singh B, Li HS, Kim YK, Kang SK, Nah JW, et al. Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials 2014;35 (7):2365–73.

[130] Yoo MK, Kang SK, Choi JH, Park IK, Na HS, Lee HC, et al. Targeted delivery of chitosan nanoparticles to Peyers patch using M cell-homing peptide selected by phage display technique. Biomaterials 2010;31 (30):7738–47.

[131] Singh B, Maharjan S, Jiang T, Kang SK, Choi YJ, Cho CS. Attuning hydroxypropyl methylcellulose phthalate to oral delivery vehicle for effective and selective delivery of protein vaccine in ileum. Biomaterials 2015;59:144–59.
[132] Singh B, Maharjan S, Jiang T, Kang SK, Choi YJ, Cho CS. Combinatorial approach of antigen delivery using M cell-homing peptide and mucoadhesive vehicle to enhance the efficacy of oral vaccine. Mol Pharm 2015;12(11):3816–28.

[133] Reineke J, Cho DY, Dingle YL, Cheifetz P, Laulicht B, Lavin D, et al. Can bioadhesive nanoparticles allow for more effective particle uptake from the small intestine? J Control Release 2013;170(3):477–84.

[134] Salman HH, Irache JM, Gamazo C. Immunoadjuvant capacity of flagellin and mannosamine-coated poly (anhydride) nanoparticles in oral vaccination. Vaccine 2009;27(S5):4784–90.

[135] Abkar M, Fasahi-Ramandi M, Kooshki H, Lotfi AS. Intraperitoneal immunization with urease loaded N-trimethyl chitosan nanoparticles elicits high protection against Brucella melitensis and Brucella abortus infections. Immunol Lett 2018;199:53–60.

[136] Kole S, Kumari R, Anand D, Kumar S, Sharma R, Tripathi G, et al. Nanojugation of bicistronic DNA vaccine against Edwardsiella tarda using chitosan nanoparticles: evaluation of its protective efficacy and immune modulatory effects in Labeo rohita vaccinated by different delivery routes. Vaccine 2018;36(16):2155–65.

[137] Pathinayake PS, Gayan Chathuranga WA, Lee HC, Chowdhury MYE, Sung MH, Lee JS, et al. Inactivated enterovirus 71 with poly-gamma-glutamic acid/chitosan nanoparticles (PC NPs) induces high cellular and humoral immune responses in BALB/c mice. Arch Virol 2018;163(8):2073–83.

[138] Walke S, Srivastava G, Routaray CB, Dhavale D, Pai K, Doshi J, et al. Preparation and characterization of microencapsulated DwPT trivalent vaccine using water soluble chitosan and its in-vitro and in-vivo immunological properties. Int J Biol Macromol 2018;107(Pt B):2044–56.

[139] Xu B, Zhang W, Chen Y, Xu Y, Wang B, Zong L. Eudragit(R) L100-coated mannosylated chitosan nanoparticles for oral protein vaccine delivery. Int J Biol Macromol 2018;113:534–42.

[140] Bhavsar C, Momin M, Ghatar S, Omri A. Functionalized and graft copolymers of chitosan and its pharmaceutical applications. Expert Opin Drug Deliv 2017;14(10):1189–204.

[141] Islam MA, Firdous J, Choi YJ, Yun CH, Cho CS. Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review. Int J Nanomedicine 2012;7:6077–93.

[142] Mi FL, Wu YY, Lin YH, Sonaje K, Ho YC, Chen CT, et al. Oral delivery of peptide drugs using nanoparticles self-assembled by poly(gamma-glutamic acid) and a chitosan derivative functionalized by trimethylolation. Bioconjug Chem 2008;19(6):1248–55.

[143] Nomura D, Saito M, Takahashi Y, Takahashi Y, Takakura Y, Nishikawa M. Development of orally-deliverable DNA hydrogel by microemulsification and chitosan coating. Int J Pharm 2018;547(1–2):556–62.

[144] Onuigbo E, Iseghohimhen J, Chah K, Gyang M, Attama A. Chitosan/alginate microparticles for the oral delivery of fowl typhoid vaccine: innate and acquired immunity. Vaccine 2018;36(33):4973–8.

[145] Oliveira CR, Rezende CM, Silva MR, Pego AP, Borges O, Goes AM. A new strategy based on SmRho protein loaded chitosan nanoparticles as a candidate oral vaccine against schistosomiasis. PLoS Negl Trop Dis 2012;6(11):e1894.

[146] Shukla A, Mishra V, Bhoop BS, Katare OP. Alginate coated chitosan microparticles mediated oral delivery of diphtheria toxoid. Part A. Systematic optimization, development and characterization. Int J Pharm 2015;495(1):220–33.

[147] Hosseini M, Dobakhht F, Pakzad SR, Ajdary S. Immunization with single oral dose of alginate-encapsulated BCG elicits effective and long-lasting mucosal immune responses. Scand J Immunol 2015;82(6):489–97.

[148] Pastor M, Esquisabel A, Talavera A, Ano G, Fernandez S, Cedre B, et al. An approach to a cold chain free oral cholera vaccine: in vitro and in vivo characterization of Vibrio cholerae gastro-resistant microparticles. Int J Pharm 2013;448(1):247–58.

[149] Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Kahl-McDonagh M, Wong-Gonzalez A, et al. Oral vaccination with microencapsuled strain 19 vaccine confers enhanced protection against Brucella abortus strain 2308 challenge in red deer (Cervus elaphus elaphus). J Wildl Dis 2009;45(4):1021–9.

[150] Sun H, Pan H, Yang Z, Shi M. The immune response and protective efficacy of vaccination with oral micro-particle Aeromonas sobria vaccine in mice. Int Immunopharmacol 2007;7(9):1259–64.

[151] Sun Y, Liu CS, Sun L. Identification of an Edwardsiella tarda surface antigen and analysis of its immunoprotective potential as a purified recombinant subunit vaccine and a surface-anchored subunit vaccine expressed by a fish commensal strain. Vaccine 2010;28(40):6603–8.

[152] Clark S, Cross ML, Smith A, Court P, Vipond J, Nadian A, et al. Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guerin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis. Vaccine 2008;26(46):5791–7.
[153] De Smet R, Allais L, Cuvelier CA. Recent advances in oral vaccine development: yeast-derived beta-glucan particles. Hum Vaccin Immunother 2014;10(5):1309–18.

[154] Soto ER, Ostroff GR. Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery. Bioconjug Chem 2008;19(4):840–8.

[155] De Smet R, Demoor T, Verschuere S, Dullaers M, Ostroff GR, Leclercq G, et al. beta-Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination. J Control Release 2013;172(3):671–8.

[156] Huang H, Ostroff GR, Lee CK, Wang JP, Specht CA, Levitz SM. Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect Immun 2009;77(5):1774–81.

[157] Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature 2001;413(6851):36–7.

[158] Soares E, Jesus S, Borges O. Oral hepatitis B vaccine: chitosan or glucan based delivery systems for efficient HBsAg immunization following subcutaneous priming. Int J Pharm 2018;535(1–2):261–71.

[159] Azegami T, Itoh H, Kiyono H, Yuki Y. Novel transgenic rice-based vaccines. Arch Immunol Ther Exp (Warsz) 2015;63(2):87–99.

[160] Sohrab SS, Suhail M, Kamal MA, Husen A, Azhar EI. Recent development and future prospects of plant-based vaccines. Curr Drug Metab 2017;18(9):831–41.

[161] Rybicki EP. Plant-made vaccines and reagents for the One Health initiative. Hum Vaccin Immunother 2017;13(12):2912–17.

[162] Nochi T, Takagi H, Yuki Y, Yang L, Masumura T, Mejima M, et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci U S A 2007;104(26):10986–91.

[163] Tokuhara D, Yuki Y, Nochi T, Kodama T, Mejima M, Kurokawa S, et al. Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc Natl Acad Sci U S A 2010;107(19):8794–9.

[164] Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991;338(8774):1055–9.

[165] Peters W, Brandt JR, Lindbloom JD, Martinez CJ, Scallan CD, Trager GR, et al. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine 2013;31(13):1752–8.

[166] Azegami T, Yuki Y, Hayashi K, Hishikawa A, Sawada SI, Ishige K, et al. Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents. J Hypertens 2017;36(2):387–94.

[167] Riese P, Sakhivel P, Trittell S, Guzman CA. Intranasal formulations: promising strategy to deliver vaccines. Expert Opin Drug Deliv 2014;11(10):1619–34.

[168] Azegami T, Itoh Y, Nakahashi R, Itoh H, Kiyono H. Nanogel-based nasal vaccines for infectious and lifestyle-related diseases. Mol Immunol 2018;98:19–24.

[169] Azegami T, Yuki Y, Sawada S, Mejima M, Ishige K, Akiyoshi K, et al. Nanogel-based nasal ghrelin vaccine prevents obesity. Mucosal Immunol 2017;10(5):1351–60.

[170] Pires A, Fortuna A, Alves G, Falcao A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 2007;12(3):288–311.

[171] Dahl R, Mygind N. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev 1998;29(1–2):3–12.

[172] Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002;7(23):1184–9.

[173] Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J Pharm Sci 2007;96(3):473–83.

[174] Heurtault B, Gentine P, Thomann JS, Baehr C, Frisch B, Pons F. Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity. Pharm Res 2009;26(2):276–85.

[175] Date Y, Ebisawa M, Fukuda S, Shima H, Obata Y, Takahashi D, et al. NALT M cells are important for immune induction for the common mucosal immune system. Int Immunol 2017;29(10):471–8.

[176] Petersson P, Hedenskog M, Alves D, Brytting M, Schroder U, Linde A, et al. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination. Vaccine 2010;28(39):6491–7.

[177] Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, et al. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine 2012;30(2):466–74.

[178] Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, et al. Synthetic double-stranded RNA poly (I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005;79(5):2910–19.

[179] Ainai A, Suzuki T, Tamura SI, Hasegawa H. Intranasal administration of whole inactivated influenza virus vaccine as a promising influenza vaccine candidate. Viral Immunol 2017;30(6):451–62.
Ainai A, Tamura S, Suzuki T, Ito R, Asanuma H, Tanimoto T, et al. Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine. J Med Virol 2012;84(2):336–44.

Ainai A, Tamura S, Suzuki T, van Riet E, Ito R, Odagiri T, et al. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Hum Vacc Immunother 2013;9(9):1962–70.

Aoshi T. Modes of action for mucosal vaccine adjuvants. Viral Immunol 2017;30(6):463–70.

Rhee JH, Lee SE, Kim SY. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res 2012;1(1):50–63.

Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 2004;350(9):896–903.

Connell TD. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev Vaccines 2007;6(5):821–34.

Fukuyama Y, Okada K, Yamaguchi M, Kiyono H, Mori K, Yuki Y. Nasal administration of cholera toxin as a mucosal adjuvant damages the olfactory system in mice. PLoS One 2015;10(9):e0139368.

Lin YL, Chow YH, Huang LM, Hsieh SM, Cheng PY, Hu KC, et al. A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge. Sci Rep 2018;8(1):10713.

Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 2011;29(34):5731–9.

Fukuyama Y, Ikeda Y, Ohori J, Sugita G, Aso K, Fujihashi K, et al. A molecular mucosal adjuvant to induce IL-17-secreting TRM cells. Mucosal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells. Mucosal Immunol. 2018;11(6):1763–76.

Allen AC, Wilk MM, Misiak A, Borkner L, Murphy D, Mills KHG. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells. Mucosal Immunol. 2018;11(6):1763–76.

Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005;57(11):1640–65.

Baudner BC, O’Hagan DT. Bioadhesive delivery systems for mucosal vaccine delivery. J Drug Target 2010;18(10):752–70.

Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009;61(2):158–71.

Witten J, Samad T, Ribbeck K. Selective permeability of mucus barriers. Curr Opin Biotechnol 2018;52:124–33.

Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev 2009;61(2):75–85.

Schneider CS, Xu Q, Boylan NJ, Chisholm J, Tang BC, Schuster BS, et al. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci Adv 2017;3(4):e1601556.

Wang YY, Lai SK, So C, Schneider C, Cone R, Hanes J. Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure. PLoS One 2011;6(6):e21547.

Comfort C, Garrastazu G, Pozzoli M, Sonvico F. Opportunities and challenges for the nasal administration of nanoemulsions. Curr Top Med Chem 2015;15(4):356–68.

Wong PT, Wang SH, Ciotti S, Makidon PE, Smith DM, Fan Y, et al. Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity. Mol Pharm 2014;11(2):531–44.

Bielsinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker Jr. JR. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2008;24(2):271–81.

Heurtault B, Frisch B, Pons F. Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv 2010;7(7):829–44.

Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004;22(15):1903–13.

Ingvarsson PT, Rasmussen IS, Viaene M, Irlrik PJ, Nielsen HM, Foged C. The surface charge of liposomal adjuvants is decisive for their interactions with the Calu-3 and A549 airway epithelial cell culture models. Eur J Pharm Biopharm 2014;87(3):480–8.

Lopes LM, Chain BM. Liposome-mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen. Eur J Immunol 1992;22(1):287–90.

Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishio K, et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997;159(7):3638–47.
REFERENCES

[206] Jiang PL, Lin HJ, Wang HW, Tsai WY, Lin SF, Chien MY, et al. Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity. Acta Biomater 2015;11:356–67.

[207] Wang D, Christopher ME, Nagata LP, Zabielski MA, Li H, Wong JP, et al. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J Clin Virol 2004;31(Suppl.1):S99–106.

[208] McNeela EA, O’Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 2000;19(9–10):1188–98.

[209] Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glangsbeek HL, et al. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. J Control Release 2009;140(2):126–33.

[210] Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 1998;16(20):2039–46.

[211] McNeela EA, Jabbal-Gill I, Illum L, Pizza M, Rappuoli R, Podda A, et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004;22(8):909–14.

[212] Hagenaars N, Mania M, de Jong P, Que I, Nieuwland R, Slutter B, et al. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. J Control Release 2010;144(1):17–24.

[213] Jabbal-Gill I, Watts P, Smith A. Chitosan-based delivery systems for mucosal vaccines. Expert Opin Drug Deliv 2012;9(9):1051–67.

[214] Zhang J, Xia W, Liu P, Cheng Q, Tahirou T, Gu W, et al. Chitosan modification and pharmaceutical/biomedical applications. Mar Drugs 2010;8(7):1962–87.

[215] Dodane V, Amin Khan M, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999;182(1):21–32.

[216] Vicente S, Peleteiro M, Díaz-Freitas B, Sanchez A, Gonzalez-Fernandez A, Alonso MJ. Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy. J Control Release 2013;172(3):773–81.

IV. CURRENT AND NEW APPROACHES FOR MUCOSAL VACCINE DELIVERY
Further Reading

Brandhonneur N, Loizel C, Chevanne F, Wakeley P, Jestin A, Le Potier MF, et al. Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres. Int J Pharm 2009;373(1-2):16–23.

Jia Y, Krishnan L, Omri A. Nasal and pulmonary vaccine delivery using particulate carriers. Expert Opin Drug Deliv 2015;12(6):993–1008.

Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, et al. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009;4(9):e6999.

Mansoor F, Earley B, Cassidy JP, Markey B, Foster C, Doherty S, et al. Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice. Res Vet Sci 2014;96(3):551–7.

Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008;38(10):2636–49.

Pan L, Zhang Z, Lv J, Zhou P, Hu W, Fang Y, et al. Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles. Int J Nanomedicine 2014;9:5603–18.

Tamura S, Yamanaka A, Shimohara M, Tomita T, Komase K, Tsuda Y, et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 1994;12(5):419–26.

Therien HM, Shahum E. Importance of physical association between antigen and liposomes in liposomes adjuvanticity. Immunol Lett 1989;22(4):253–8.

van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000;165(9):4778–82.